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    Abstract 
Purpose: To determine the efficacy of selective laser trabeculoplasty (SLT) in lowering intra-
ocular pressure (IOP) levels and reducing the number of medications in patients with open 
angle glaucoma (OAG) or ocular hypertension (OHT).  
Methods: A systematic review was conducted by searching various databases including 
MEDLINE (Ovid), EMBASE (Ovid), CINAHL, Cochrane Library, Web of Science- Core 
Collections, BIOSIS Previews, and Scopus. Duplicates were removed and articles were 
screened using EPPI Reviewer 4. A meta-analysis was conducted using STATA 13.0. 
Weighted mean difference (WMD) was computed and the heterogeneity statistic was 
assessed using the I2. Fixed and random effects models were computed based on 
heterogeneity.  
Results: We identified 31 articles that met our inclusion criteria. We found that Sequential 
SLT versus pharmacotherapy had an IOP-lowering effect favoring pharmacotherapy: WMD= 
5.92% (95% CI [3.06, 8.79]) and WMD= 2.73% (95% CI [0.24, 5.23]) at 6 and 12 months, 
respectively. Adjunctive SLT had a greater IOP-lowering effect compared to 
pharmacotherapy, WMD= -8.98% (95% CI [-17.19, -0.77]). A significant reduction in the 
post-operative medications was observed up to 17 months. No serious complications were 
reported.  
Conclusion: Adjunctive SLT may lead to significant reduction in IOP compared to topical 
medications. Additional studies need to be conducted on SLT alone, without previous 
treatment in order to determine its IOP-lowering effect.  
 
 
 
Keywords 
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agonists, Pharmacotherapy 
ii 
  
 
Abbreviations 
ACG: Angle Closure Glaucoma 
ALT: Argon Laser Trabeculoplasty 
CAI: Carbonic Anhydrase Inhibitor 
CI: Confidence Interval 
ELT: Excimer Laser Trabeculoplasty 
Emtree: Embase Subject Heading 
IOP: Intra-ocular Pressure 
IOPR: Intra-ocular Pressure Reduction 
LPI: Laser Peripheral Iriodotomy 
MeSH: Medical Subject Heading 
mL: milliliter 
Mm Hg: Millimeters of Mercury 
N: Number of Eyes 
ND:YAG: Neodymium: Yttrium-aluminium garnet-laser  
NTG: Normal Tension Glaucoma 
OAG: Open-angle Glaucoma 
OHIP: Ontario Health Insurance Plan 
OHT: Ocular Hypertension 
p:p-value 
PACG: Primary Angle Closure Glaucoma 
PGA: Prostaglandin Analogs 
POAG: Primary Open-angle Glaucoma 
RCR: Retrospective Chart Review 
iii 
  
 
RCT: Randomized Clinical Trial 
SD: Standard Deviation 
SLT: Selective Laser Trabeculoplasty 
TM: Trabecular Meshwork 
WMD: Weighted Mean Difference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
  
 
Acknowledgements 
I would like to thank my supervisors, Dr. Monali Malvankar, and Dr. Amardeep Thind for 
providing me with support and guidance throughout the design and writing of this thesis. 
Without your continued support and expertise, the completion of this thesis would not have 
been possible.  
I would like to extend my gratitude to Dr. Kelly Anderson, and Dr. Cindy Hutnik for offering 
valuable insight on my thesis. I would also like to thank Emaad Mohammad for agreeing to 
be the secondary screener for the systematic review and quality assessment.  
Finally, I would like to thank my family and friends for their encouragement and support 
throughout my graduate studies. I would especially like to thank my mother for having 
confidence in me, not only over the past two years but throughout all of my life endeavors.  
 
 
 
 
 
 
 
 
 
 
 
 
v 
  
 
Table of Contents 
Abstract ................................................................................................................................ i 
Abbreviations ................................................................................................................. ii 
Acknowledgements ....................................................................................................... iv 
Table of Contents ........................................................................................................... v 
List of Tables ...................................................................................................................... x 
List of Figures .................................................................................................................... xi 
List of Appendices ............................................................................................................ xii 
Chapter 1 ............................................................................................................................. 1 
1.1 Introduction ............................................................................................................. 1 
1.2 Epidemiology of Glaucoma .................................................................................... 1 
1.3 Organization of Thesis ............................................................................................ 2 
Chapter 2 ............................................................................................................................. 3 
2 Literature Review ........................................................................................................... 3 
2.1 Definition and History of Glaucoma....................................................................... 3 
2.2 Pathophysiology of Glaucoma ................................................................................ 3 
2.3 Types of Glaucoma ................................................................................................. 4 
2.3.1 Open-angle Glaucoma ................................................................................ 4 
2.3.2 Ocular Hypertension ................................................................................... 5 
2.3.3 Angle Closure Glaucoma ............................................................................ 5 
2.4 Glaucoma Risk Factors ........................................................................................... 6 
2.4.1 Intraocular Pressure (IOP) .......................................................................... 6 
2.4.2 Demographic Factors .................................................................................. 6 
2.4.3 Medical Factors ........................................................................................... 7 
2.5 Assessment of Glaucoma ......................................................................................... 7 
vi 
  
 
2.5.1 Tonometry ...................................................................................................... 7 
2.5.2 Gonioscopy .................................................................................................... 8 
2.5.3 Ophthalmoscopy ............................................................................................ 8 
2.5.4 Perimetry ........................................................................................................ 8 
2.6 Treatment of Glaucoma............................................................................................ 9 
2.6.1 Medications .................................................................................................... 9 
2.6.2 Laser Therapy .............................................................................................. 10 
2.6.2.1 Application of SLT ....................................................................... 11 
2.6.3 Surgical Treatment ....................................................................................... 11 
2.6.4 Aim of Treatment ......................................................................................... 12 
2.6.5 Treatment Strategies .................................................................................... 12 
2.7 Cost of Treatment ................................................................................................... 13 
2.7.1 Cost of Medical Therapy ............................................................................. 13 
2.7.2 Cost of Laser Treatment and Surgery .......................................................... 13 
2.7.3 Cost of Medical Treatment compared to Laser Treatment .......................... 14 
2.8 Purpose ................................................................................................................... 15 
2.8.1 Efficacy of SLT............................................................................................ 15 
2.8.2 Previous Systematic Reviews and Meta-Analyses ...................................... 15 
2.8.3 Gap in Knowledge ....................................................................................... 16 
2.8.4 Aims and Objectives .................................................................................... 17 
Chapter 3 ........................................................................................................................... 18 
3 Methods ........................................................................................................................ 18 
3.1 Databases Searched ............................................................................................... 18 
3.2 Grey Literature Sources ........................................................................................ 18 
3.3 Inclusion and Exclusion Criteria ........................................................................... 19 
vii 
  
 
3.4 Article Screening Process ..................................................................................... 19 
3.4.1 Cohen’s Kappa Statistic ............................................................................ 20 
3.5 Outcomes .............................................................................................................. 21 
3.5.1 IOP Reduction ........................................................................................... 21 
3.5.2 Medication Reduction ............................................................................... 21 
3.5.3 Complications ........................................................................................... 22 
3.6 Data Extraction ..................................................................................................... 22 
3.6.1 Baseline and Follow-up ............................................................................ 22 
3.7 Quality Assessment ............................................................................................... 22 
3.8 Quantitative Measures used in the Meta-Analysis ................................................ 23 
3.8.1 Meta-Analysis ........................................................................................... 23 
3.8.1.1 Effect Measures .......................................................................... 23 
3.8.1.2 Heterogeneity ............................................................................. 24 
3.8.1.3 Random-Effects and Fixed-Effect Models ................................. 25 
3.9 Subgroup Analysis ................................................................................................ 26 
3.9.1 SLT versus Medications Studies ............................................................... 26 
3.9.2 Adjunctive SLT Studies ............................................................................ 26 
3.10 Sensitivity Analysis .............................................................................................. 27 
3.11 Publication Bias .................................................................................................... 27 
3.12 Missing Data ......................................................................................................... 28 
Chapter 4 ........................................................................................................................... 29 
4 Results .......................................................................................................................... 29 
4.1 Study Characteristics ............................................................................................ 29 
4.1.1 SLT versus Medications Studies ............................................................... 29 
4.1.2 Adjunctive SLT Studies ............................................................................ 32 
viii 
  
 
4.2 Study Selection ..................................................................................................... 38 
4.2.1 Screening................................................................................................... 38 
4.2.2 Inter-rater Agreement................................................................................ 40 
4.3 Quality Assessment ............................................................................................... 40 
4.3.1 Downs and Black Risk of Bias Assessment ............................................. 40 
4.4 Publication bias ..................................................................................................... 43 
4.5 Impact on Intra-ocular Pressure Reduction (IOPR) .............................................. 46 
4.5.1 IOPR after SLT ......................................................................................... 46 
4.5.2 IOPR comparing SLT versus Medications ............................................... 49 
4.5.3 WMD in IOPR Comparing Sequential SLT with Medications ................ 51 
4.5.4 WMD in IOPR Comparing Adjunctive SLT with Medications ............... 53 
4.5.5 IOPR comparing Primary SLT with Medications .................................... 55 
4.6 Impact on Medications .......................................................................................... 55 
4.6.1 Percent Reduction in Number of Medications after SLT ......................... 55 
4.6.2 WMD of Pre-and-Post SLT Medications ................................................. 58 
4.6.3 Subgroup Analysis by SLT Degree .......................................................... 60 
4.6.4 Subgroup Analysis by Study Design ........................................................ 63 
4.7 Impact on Adverse Events .................................................................................... 66 
4.7 Sensitivity Analysis .............................................................................................. 68 
4.8 Summary of Findings ............................................................................................ 73 
Chapter 5 ........................................................................................................................... 74 
5 Discussion .................................................................................................................... 74 
5.1 Summary of Quantitative Results ......................................................................... 74 
5.2 Interpretation of Results ........................................................................................ 75 
5.3 Strengths and Limitations ..................................................................................... 76 
ix 
  
 
5.4 Implications of Practice and Future Research ...................................................... 77 
5.5 Conclusion ............................................................................................................ 79 
References ........................................................................................................................ 80 
Appendices ........................................................................................................................ 91 
Curriculum Vitae ............................................................................................................ 103 
x 
  
 
List of Tables 
Table 1: Baseline Characteristics of Included Studies Comparing SLT with Medications .... 30 
Table 2: SLT Characteristics of Included Studies Comparing SLT with Medications .......... 31 
Table 3: Baseline Characteristics of Studies Evaluating Adjunctive SLT ............................. 33 
Table 4: SLT Characteristics of Studies Evaluating Adjunctive SLT .................................... 35 
Table 5: Medication Details of Studies Evaluating Adjunctive SLT ..................................... 36 
Table 6: Downs and Black Quality Assessment Average Score for each Category ............... 41 
Table 7: Kappa Statistics Computed for Individual Studies ................................................... 42 
Table 8:Intra-ocular Pressure Percentage Reduction Post SLT .............................................. 47 
Table 9:Follow-up of Included Studies Comparing SLT with Medications........................... 50 
Table 10: Medication Reduction from Baseline in Included Studies ..................................... 56 
Table 11: Reported Adverse Events Post SLT Treatment ...................................................... 67 
Table 12: Summary of Main Findings .................................................................................... 73 
 
xi 
  
 
List of Figures 
Figure 1: PRISMA Flow Diagram .......................................................................................... 39 
Figure 2: Funnel Plot for Studies Evaluating SLT versus Medications ................................. 44 
Figure 3: Funnel Plot for Studies Evaluating SLT as an Adjunctive Treatment .................... 45 
Figure 4: Forest Plot for Studies Evaluating Sequential SLT versus Medications ................. 52 
Figure 5: Forest Plot for Studies Evaluating Adjunctive SLT versus Medications at 6 months 
Follow-up ................................................................................................................................ 54 
Figure 6: Forest Plot of Medications Pre-and-Post SLT ......................................................... 59 
Figure 7:Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 6-11 Months 
Follow-up ................................................................................................................................ 61 
Figure 8:Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 12-17 Months 
Follow-up ................................................................................................................................ 62 
Figure 9: Forest Plot of Medications Pre-and-Post SLT by Study Design at 6-11 Months 
Follow-up ................................................................................................................................ 64 
Figure 10: Forest Plot of Medications Pre-and-Post SLT by Study Design at 12-17 Months 
Follow-up ................................................................................................................................ 65 
Figure 11: Sensitivity Analysis for Studies Evaluating Sequential SLT versus Medications 70 
Figure 12: Sensitivity Analysis for Studies Evaluating Adjunctive SLT versus Medications 71 
Figure 13: Sensitivity Analysis for Studies Evaluating the Pre-and-Post SLT Number of 
Medications ............................................................................................................................. 72 
xii 
  
 
 
List of Appendices 
Appendix 1: PRISMA Checklist ............................................................................................. 91 
Appendix 2: Search Strategy .................................................................................................. 93 
Appendix 3: Screening Questions ........................................................................................... 99 
Appendix 4: Data Extraction Sheet for Studies Evaluating SLT versus Medications .......... 100 
Appendix 5: Data Extraction Sheet for Studies Evaluating SLT as Adjunctive Treatment . 100 
Appendix 6: Downs and Black Checklist ............................................................................. 101 
 
 
1 
  
 
Chapter 1  
 
1.1 Introduction 
This thesis aims to evaluate selective laser trabeculoplasty (SLT) as an intervention to 
treat patients who are diagnosed with open-angle glaucoma (OAG) or ocular 
hypertension (OHT). Ophthalmologists use glaucoma medications as their primary form 
of treatment for glaucoma patients1, due to  robust data supporting their efficacy2–10.  SLT 
is a laser treatment option that was introduced by Dr. Latina and colleagues in 199511.The 
first clinical study published that reported on the efficacy of SLT was in 199812. Over the 
past two decades, there has been a vast amount of literature that has been published on 
the efficacy of SLT. We conducted this systematic review and meta-analysis with the 
intention of assessing the influence of SLT on intra-ocular pressure (IOP) levels and its 
impact on reducing the amount of required topical glaucoma medications.  
1.2 Epidemiology of Glaucoma 
Glaucoma is the second most common cause of legal blindness in industrialized 
nations13. In 2013, the worldwide prevalence of glaucoma for a population aged 40 to 80 
years was estimated to be approximately 3.54% (95% CI [2.09%, 5.82%]) of the global 
population14. Specifically, in North America, the prevalence of glaucoma was estimated 
to be 3.55% (95% CI [1.98%, 5.81%])14. The incidence is estimated to be approximately 
0.5 to 2.5% per year15.  By 2020 there will be approximately 79.6 million people 
estimated to be affected by glaucoma worldwide and 11,114,117 people (95% CI [7 947 
390,  16 230 278]) will become bilaterally blind from glaucoma16. By the year 2040, the 
global prevalence of glaucoma is expected to rise to 111.8 million14.  
 
The prevalence numbers are assumed to be underestimated given that approximately one-
third of individuals with glaucoma are undiagnosed17. If glaucoma goes untreated, it can 
lead to blindness. Glaucoma is one of the top three causes of visual impairment and 
blindness worldwide18. The percentage of people who go blind per year because of 
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glaucoma is approximately 0.55%15.Blindness is defined as a visual acuity score of less 
than 3/6019, which means that what a person sees at three meters, a person with normal 
vision sees at 60 meters. Since more than 80% of visual impairment is avoidable18, not 
diagnosing and not treating glaucoma puts an unnecessary strain on the health care 
system.  
1.3 Organization of Thesis 
This thesis is organized into four main sections. Chapter 2 provides a detailed literature 
review including the history of glaucoma, the types and treatment of glaucoma, the costs 
associated with glaucoma treatment, and the purpose and objectives of this thesis. Chapter 
3 provides details on the methodological approach used to investigate the research 
questions. It discusses the search strategies, inclusion and exclusion criteria, the article 
screening process, and the quantitative measures used to analyze the results. Chapter 4 
provides figures, tables and a summary of the results produced. Chapter 5 provides a 
comprehensive discussion on the results including the overall interpretation of the findings, 
the strengths and limitations, and future policy and research implications.  
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Chapter 2  
2 Literature Review 
2.1 Definition and History of Glaucoma 
“Glaucoma” comes from the Greek word glaucosis, which is defined as the ‘blue-green 
hue of the affected eye’20. In the 10th century, Arabian physicians noted the connection 
between glaucoma and increased pressure inside the eye. In 1622, Richard Bannister  
noted that chronic glaucoma could be associated with elevated intraocular pressure, and 
was the first to document these findings in English21. From the 10th century to the 19th 
century, ophthalmologists from around the world have noted similar characteristics of 
increased pressure inside the eye. Elevated intra-ocular pressure (IOP) levels were 
accepted as a distinguishing symptom of glaucoma in the mid-19th century21. 
Several clinical studies conducted in the 1990s have shown that many glaucoma cases 
had other causes besides elevated intraocular pressure levels20. The definition of 
glaucoma shifted from being solely defined by elevated IOP levels to being defined by its 
optic nerve damage and associated vision loss20. 
2.2 Pathophysiology of Glaucoma 
A clear fluid referred to as the aqueous humor is produced by the ciliary body and fills 
the anterior and posterior chambers of the eye22. The rate of fluid production is 
approximately 2.5 microliters/minute22.  Fluid inside the eye must be under some 
pressure at all times to keep it from collapsing. The fluid exits the anterior chamber 
through the trabecular meshwork (TM) or the uveoscleral outflow. The TM is a sponge-
like structure which consists of three layers23. The resistance to fluid outflow increases as 
fluid passes each layer of the TM and enters the Schlemm’s canal. Fluid that does not 
flow to the TM, flows into the supraciliary space and ciliary muscle and then goes to the 
scleral substance or the emissarial canals or is absorbed into the uveal blood vessel; this 
outflow is called the uveoscleral outflow24. The uveoscleral outflow only accounts for 
approximately 4 to 45% of aqueous humor outflow24. Treatment is aimed at the TM 
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because the TM outflow is IOP dependent, while the uveoscleral outflow is independent 
of IOP24.  
Too much pressure caused from not having enough fluid exiting the eye may result in 
elevated eye pressures. Pressure on the optic nerve may result in optic nerve damage22. 
The optic nerve is located at the back of the eye and has approximately 1.2 million nerve 
fibers25. The optic nerve travels from the back of each eye and joins together at the optic 
chiasm22. Electrical impulses travel along the optic nerve, optic tract, lateral geniculate 
body and finally the occipital lobe where the images are interpreted by the brain22. Due to 
the damage of the optic nerve, the retinal nerve cells eventually die, disrupting the 
connection between the eye and the brain26, resulting in vision loss.  
The main distinguishing feature from other neuropathic diseases is that the presence of 
glaucoma results in a progressively large optic nerve cup25. As the optic nerve loses nerve 
fibers, the cup becomes larger. The cup-to-disc ratio ranges from 0 to 125. The larger the 
cup-to-disc ratio, the larger the optic nerve damage. Another factor that makes glaucoma 
different from other neuropathic diseases is that the treatment is aimed at lowering the 
intra-ocular pressure, whereas other neuropathic diseases usually have normal intra-
ocular pressure levels. 
2.3 Types of Glaucoma 
The majority of glaucoma diseases fall under one of three categories: open-angle 
glaucoma (OAG), ocular hypertension (OHT) and angle closure glaucoma. This thesis 
will focus on OAG and OHT.  
2.3.1 Open-angle Glaucoma 
The drainage angle, which is located between the cornea and the iris, is what determines 
whether a patient has open-angle glaucoma or closed-angle glaucoma27. If the drainage 
angle is open, this is referred to as OAG. OAG is generally a bilateral disease, but may 
often also be asymmetric28. OAG is characterized as either primary or secondary. Primary 
OAG accounts for almost 90% of all glaucoma cases5. Secondary OAG is any form of 
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OAG that has an identifiable cause22. Patients with OAG who have IOP levels greater 
than 21 mm Hg are referred to as high tension glaucoma patients27. Patients with 
glaucomatous nerve damage, who have IOP levels lower than 22 mm Hg, account for 
approximately 15% of all OAG cases28. These patients are referred to as normal tension 
glaucoma (NTG) patients. OAG is usually asymptomatic and patients may notice a loss 
of peripheral vision after approximately 40% of nerve fibers have been damaged28. 
2.3.2 Ocular Hypertension 
Ocular hypertensive (OHT) patients have an open drainage angle and have IOP levels 
over 21 mm Hg. They do not show signs of optic nerve damage or visual field defects29; 
this group of patients are referred to as glaucoma suspects22.  
2.3.3 Angle Closure Glaucoma 
Angle closure glaucoma (ACG) is a less common form of glaucoma, and has a drainage 
angle that is closed when it is examined by the gonioscopy  lens25. ACG is also 
characterized as primary or secondary. Primary ACG occurs when there is a pupillary 
block that cause the angle to close22. Secondary ACG is when there are underlying 
reasons other than a pupillary block that causes the angle to close. This type of glaucoma 
may be associated with symptoms of pain, nausea and decreased vision25.  
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2.4 Glaucoma Risk Factors 
There are several different risk factors associated with the development of glaucoma. The 
risk factors are divided into three different groups: elevated IOP, demographic factors, 
and medical factors.  
2.4.1 Intraocular Pressure (IOP) 
Intraocular pressure (IOP) refers to the fluid pressure in the eye30. High IOP levels, IOP 
levels above 21 mm Hg, is not a necessary cause for developing glaucoma, but it does 
increase the likelihood of developing the disease25. The Baltimore Eye Survey and the 
Barbados Eye Study found that IOP was an important factor correlated with higher 
prevalence and incidence rates31. It has been well-documented that the relative risk of 
developing glaucoma increases as an individual’s IOP levels increase25. 
Approximately26.1% of patients who have IOP levels greater than or equal to 35mm Hg 
have glaucoma versus only 0.7% of patients who have IOP levels less than 15mm Hg 
have glaucoma25. Also, those who have an IOP asymmetry between their eyes have a 
higher likelihood of developing glaucoma20. 
2.4.2 Demographic Factors 
Age is one of the strongest determining factors for developing glaucoma, as the 
frequency of glaucoma cases increases with age20. The majority of glaucoma cases 
develop after the age of 40 or 50 years32. The American Academy of Ophthalmology has 
recommended that those between 40 and 64 get assessed for glaucoma every 2-4 years 
and those over the age of 65 get assessed every 1-2 years25. The reason for the increase in 
risk with increasing age is that nerve fibers are lost throughout one’s lifetime26. The more 
nerve fibers are lost, the wider the cup-to-disc ratio becomes resulting in an increased risk 
of developing glaucoma22. Race also plays a role in the prevalence of glaucoma cases. It 
has been reported that African Americans are more likely than Caucasians to develop 
primary open-angle glaucoma and to become blind from it25. Asians are more likely to 
develop primary angle closure glaucoma (PACG)16. Approximately 0.3 to 2.6% of Asians 
will develop PACG compared to 0.1% to 0.6% of all other races25. 
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2.4.3 Medical Factors 
Diseases such as thyroid disease, obesity, diabetes, emphysema and cardiovascular 
disease are risk factors that may lead to glaucoma20. There is a strong positive correlation 
between taking steroids and developing glaucoma20. The IOP levels are elevated in 
approximately 16% of those on steroids20. Also, if there is a history of glaucoma in one’s 
family, the likelihood of developing glaucoma will increase32. To an extent, an 
individual’s genetic code can determine whether they can tolerate a high IOP level26.  
2.5 Assessment of Glaucoma 
Early detection of the disease is essential to prevent as much vision loss as possible. 
There are several measurement tools that ophthalmologists use to accurately diagnose 
glaucoma. Testing for glaucoma usually involves measuring the IOP levels, observing the 
optic nerve, and testing visual fields32. Results from these tests are required in order for 
an ophthalmologist to make a correct glaucoma diagnosis.  
2.5.1 Tonometry 
Tonometry is a procedure that ophthalmologists use to measure the IOP levels25. The 
Goldmann applanation tonometer is the most commonly used tool to measure IOP22 and 
is considered the gold standard30,31. An anesthetic eye drop is placed into the patients’ 
eye, then the IOP is measured by placing a biprism plastic tip against the cornea and 
flattening the cornea25.  The IOP is based on the principle that the force required to flatten 
a certain defined area of the cornea is proportional to the IOP25. IOP measurement is also 
dependent on the thickness of the cornea22. When the cornea is thick, the IOP levels are 
over estimated, and when the cornea is thin, the IOP levels are usually underestimated22. 
Other less common tools to measure tonometry include the Tonopen and the Perkens; 
these two tools are portable applanation tonometers25. The pascal dynamic contour 
tonometer, pneumatotonometer and Schiotz tonometer are also used to measure IOP 
levels25.  
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2.5.2 Gonioscopy 
Visualization of the anterior angle of the eye is referred to as gonioscopy8. Whether this 
angle is wide or narrow affects the aqueous outflow. Gonioscopy involves examining the 
angle of the anterior chamber using binocular magnification and a special 
goniolens22.Several types of goniolenses are used. Goldmann and Posner-Zeiss are two 
types that have mirrors to view the angle between the cornea and the iris22. The Koeppe 
lens is a goniolens used with an illuminator and a handheld binocular microscope22. The 
results from the gonioscopy gives an idea of whether the patient has open or closed-angle 
glaucoma.  
2.5.3 Ophthalmoscopy 
The ophthalmoscope is a tool used to assess the optic disc. Correct evaluation of the optic 
nerve head is imperative. If the optic nerve head is incorrectly classified, this can result in 
a glaucoma patient remaining untreated or a non-glaucoma patient receiving treatment33. 
To assess the optic disc, the ophthalmologist dilates the pupils with eye drops and uses a 
slit lamp with a hand held lens to observe the optic nerve32. Evaluation of the optic nerve 
requires the ophthalmologist to first assess the size of the optic nerve head26. The cup-to-
disc ratio is how the doctors assess the size of the optic disc22. Generally a cup size of 0.2 
to 0.3 is considered normal25.  The values 0.2 and 0.3 are converted into percentages; 
therefore a cup size that occupies 20% to 30% of the disc is considered normal. If the 
cup-to-disc ratio is greater than 0.5 with visual field loss and high IOP levels, then the 
patient may have glaucoma22.  
2.5.4 Perimetry 
Perimetry is the measurement of visual fields25. The visual field assessment measures 
both central and peripheral vision in order to find any blind spots that exist. The most 
common form of perimetry is when a patient is instructed to keep one eye fixed on a 
target that is directly in front of them while the other eye is covered25. The patient must 
press a button every time he/she sees a light flash. The computer records the location of 
the flash and whether the patient pressed the button22. This procedure examines the 
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sensitivity of peripheral vision to flashes of light that are briefly presented at various 
peripheral points.  
2.6 Treatment of Glaucoma 
Even though increased eye pressure is no longer included in the definition of glaucoma, 
reduction of eye pressure remains the main form of delaying the progression of optic 
nerve damage25. The primary form of treatment to prevent vision loss is 
pharmacotherapy.  
2.6.1 Medications 
Topical medications are the first line therapy for OAG. Most glaucoma medications are 
applied through eye drops or oral digestion34. There are four main classes of medications 
used to lower the eye pressure. Prostaglandin analogs are currently the most popular first 
line medication drugs because they have the fewest side effects25. Prostaglandin analogs 
work by increasing the aqueous outflow25. Latanoprost (Xalatan) was the first 
prostaglandin analog developed for glaucoma25. Travoprost (Travatan) and brimatoprost 
(Lumigan) are other prostaglandin analogs. These drugs are efficient and require once a 
day dose. Beta blockers, which are the second most commonly prescribed drugs, work by 
decreasing the aqueous production in the eye25. They are not used as frequently as 
prostaglandin analogs because they may be less effective at lowering IOP levels34. This 
class of drugs works by inhibiting the sympathetic nervous system, which is involved in 
the production of the aqueous humour34. Beta-blockers include Timolol, Levobunolol 
(Betagan), and Betaxolol (Betoptic). Timolol is the most commonly used beta-blocker25. 
Carbonic anhydrase inhibitors (CAI) are a class of drugs that work by reducing the 
aqueous production by about 40-60%22. They inhibit the enzyme carbonic anhydrase 
which reduces the fluid production25. The CAIs are not used frequently because they have 
systemic side effects that limit their long term use22. Once the patient is taken off of this 
drug, the side effects are usually reversible. These drugs are rarely used alone and are 
usually prescribed in combination with other classes of drugs. Alpha agonists are another 
class of drugs that decrease IOP levels by decreasing the production of fluid at the ciliary 
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body and they additionally help with the aqueous outflow25. The most commonly used 
drugs under this class are Brimonidine (Alphagan) and Apraclonidine (Iopidine)25. 
2.6.2 Laser Therapy 
Laser therapy has been gaining popularity. The first reported use of laser therapy, which 
is also called laser trabeculoplasty, for patients with OAG was in the 1970s, 
approximately 40 years ago35. The pressure reduction from laser therapy decreases the 
medical therapy and postpones surgery, if it is required. Argon laser trabeculoplasty 
(ALT) is a laser that was first introduced by Wise and Witter36 in 1979 through their pilot 
study. ALT uses a spot size of 50 micrometers, between 500 and 1000 megawatts of 
energy output and a pulse duration of 0.1 seconds, which is applied to the junction of the 
anterior and posterior TM35. In 1983, Anderson and Parish37 found that brief pulses of 
selectively absorbed optical radiation could cause damage to selected pigmented tissues. 
They proposed selective photothermolysis, which made precise aiming of the laser 
unnecessary because properties in the tissue provided target selectivity so that only the 
pigmented tissues would be affected by the laser38. Selective laser trabeculoplasty (SLT) 
was introduced in 1995 by Latina and Park11. The intention was to create a laser similar 
to the argon laser, but without creating collateral damage to the non-pigmented tissue in 
the TM. In 1998 Latina and colleagues12 published a pilot study and found that SLT 
treatment was effective at lowering IOP in patients with or without previous ALT 
treatment12. SLT is a frequency doubled, Q-switched neodymium: Yttrium-aluminium 
garnet-laser (ND: YAG) with a wavelength of 532nano-meters, a pulse duration of 3 
nano-seconds and a spot size of 400 micrometers 12. Because of the 3 nano-second pulse 
duration in SLT compared to the 1 second pulse duration in ALT, the electromagnetic 
energy in SLT does not have enough time to be converted into thermal energy, resulting 
in no heat being generated39. This means that SLT does not burn the TM, and that 
multiple SLT procedures are possible with minimal side effects relating to damage to the 
TM.  
Laser treatment works by directing the laser beam at the TM, causing the tissue to shrink, 
which improves the drainage of fluid through the TM and ultimately lowers the IOP22. 
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Laser treatment also stimulates the creation of new cells and helps get rid of waste in the 
TM22. A theory regarding the mechanism through which the laser procedure works to 
decrease the IOP is the result of cellular activity stimulated by the laser’s energy40.  After 
SLT is performed, there is an increase in the number of macrophages in the TM40. 
Macrophages are cells that are involved in the removal of cellular debris that is generated 
during tissue remodeling, and efficiently clear cells that have died41. This allows an 
increased outflow of the fluid from the eye40. 
2.6.2.1 Application of SLT 
The ND: YAG Q-switched laser can be administered to the TM over multiple degrees of 
application. The most common degrees of treatment over the TM as reported in published 
studies are 90, 180, 270, or 360 degrees. Furthermore, each ophthalmologist has their 
own preference on the number of laser spots to be applied, and whether to apply the laser 
spots contiguously or non-contiguously. As with any other medical procedure, the 
guiding principle for SLT treatment is to apply the least amount of treatment to the TM as 
possible in order to achieve the desired benefit42. Several studies with mixed results have 
assessed whether this difference in the application of the laser beam throughout the TM 
affects the IOP-lowering effect of SLT treatment. Several studies have reported that the 
SLT degree may make a difference43,44, or may not make any difference45,46 on the IOP-
lowering effect.  
2.6.3 Surgical Treatment 
If medical therapy or laser therapies do not work, surgical treatment is recommended. 
Trabeculectomy is the most common form of surgical treatment (often referred to as 
filtration procedure)22. This procedure reduces the IOP levels by creating another 
passageway for the fluid to flow out by removing part of the TM47. Finally, when laser or 
surgical treatment does not work, the ophthalmologist may decide to destroy the ciliary 
body, which is responsible for aqueous humor production22. 
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2.6.4 Aim of Treatment 
All treatment for glaucoma patients is aimed at lowering the IOP inside the eye. The 
Early Manifestation Glaucoma Trial48 found that lowering the IOP levels was linked to a 
decrease in glaucoma progression, and The Ocular Hypertension Treatment 
Study49concluded that IOP reduction (IOPR) lowered the chance of ocular hypertensives 
to develop glaucoma. Ophthalmologists aim to select an IOP target in which no glaucoma 
progression will occur; this IOP target is different for each patient since each patient 
reacts to treatment differently50.Other methods, such as vascular neuroprotective or 
metabolic management were conducted in animal experiments but their influence on 
glaucoma progression in humans has not yet been established in randomized clinical 
trials31. 
Additionally, ophthalmologists need to make sure that the treatment they provide is also 
reducing the IOP fluctuations. Although some studies have shown that there is no link 
between IOP fluctuations and glaucoma progression48, other studies51 have shown that 
there is a link. A patient who has an average IOP of 12 mm Hg and a fluctuation between 
11 mm Hg and 13 mm Hg has a reduced likelihood of developing glaucomatous damage 
compared to a patient who also has an average IOP of 12 mm Hg but a fluctuation 
between 10 mm Hg and 16 mm Hg50. 
2.6.5 Treatment Strategies 
Various treatment options could be available to a patient. The first treatment option is to 
put the patient on medications, and if this is unsuccessful, after at least a 4-5 week wash-
out of medications, the patient is provided laser treatment. In this study, this is referred to 
as Sequential SLT, where SLT is provided after a wash-out period of medical treatment. 
The second option is to provide medications as primary treatment, and to provide SLT 
while concurrently remaining on medical treatment. In this study, his is referred to as 
Adjunctive SLT treatment. The majority of published studies assess the clinical outcomes 
of these two groups of patients- Sequential SLT and Adjunctive SLT. The differing 
effects of these two treatment strategies remains unknown. SLT could be provided as 
13 
  
 
primary treatment and if unsuccessful, SLT is repeated or medications are given. Finally, 
a patient could be prescribed a medications-only option in which prostaglandin analogs 
are given as a first line of treatment, beta-blockers as a second line of treatment, CAIs as 
third and alpha agonists as a fourth line of treatment. This thesis will focus on the 
efficacy of SLT when it is provided as primary, sequential or adjunctive treatment and 
the efficacy of medications-only treatment.  
2.7 Cost of Treatment 
2.7.1 Cost of Medical Therapy 
Some patients prefer pharmacotherapy because it is a less invasive treatment 
alternative52. Also, any side effects associated with pharmacotherapy usually cease when 
the medications are discontinued. Since glaucoma is a chronic condition, treatment 
becomes costly over a patient’s lifetime. If an individual is over the age of 65 and has a 
valid Ontario Health Card, he/she qualifies for the Ontario Drug Benefit Plan53. The 
Ontario Drug Benefit Plan covers the majority of the anti-glaucoma medications 
prescribed. If an individual is not 65 yet, the Trillium Drug Program is available for 
persons who have an Ontario health card54. All of the drugs that are covered by the 
Ontario Drug Benefit Plan are also covered in the Trillium Drug Plan. The difference is 
that someone who is under the Trillium Drug Plan is required to pay a deductible of 
approximately 4% of their net income per year into this plan54. Additionally, if the 
individual is employed, some employers will offer medical drug coverage. 
2.7.2 Cost of Laser Treatment and Surgery 
The average cost of bilateral SLT treatment at 180 degrees was $370 in 200355. The costs 
of laser therapy have not changed much over the past decade. Seider et al56 found that the 
average cost of bilateral SLT is approximately $675.76. Fortunately in Ontario, patients 
with glaucoma at any age who are Ontario Health Insurance Plan (OHIP) covered can 
receive free yearly eye examinations. Any follow-up assessments are also covered. 
Furthermore, if the patient requires SLT treatment, it is completely covered through 
OHIP.  
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2.7.3 Cost of Medical Treatment compared to Laser Treatment 
A cost comparison study was conducted by Seider et al56comparing patients who were 
provided SLT treatment concurrently with medication treatment (Adjunctive SLT) and 
patients who were only prescribed medications. The Adjunctive SLT group had bilateral 
treatment and was required to take a 2.5 milliliters (mL) medication once a day. The 
medications-only group was required to take a 5mL medication 2 to 3 times daily. They 
found that when SLT was compared to brand name glaucoma medications, SLT became 
less costly within one year, but when SLT was compared to generic medications, SLT 
became less costly between 13 and 40 months.  Stein et al1 conducted an analysis looking 
at the cost effectiveness of treating OAG patients with prostaglandin analogs, laser 
trabeculoplasty, or no treatment and they found that prostaglandin analogs were cost 
effective and provided a better health-related quality of life. However, these results 
assumed that there was perfect compliance with glaucoma medications, which is often 
not the case. Further, authors concluded that if a patient did not adhere to the 
medications, laser treatment would be a cost effective alternative. Finally, Lee and 
Hutnik55 conducted a 6-year cost comparison of Primary SLT with medical therapy. They 
found that when SLT was repeated every two years compared to mono-drug therapy, SLT 
became cost effective in the second year. When a patient who received SLT treatment 
every two years was compared with a patient who was on combination drug therapy, SLT 
was consistently cost effective. Combination drug therapy includes patients who are on 
two or more glaucoma medications. Lee and Hutnik55 reported a cost savings for SLT 
patients of $206.54, $1668.84, $2992.62 over 6 years compared to patients on mono-, bi- 
and tri- drug therapy.  
Based on these studies, the number of medications, as well as generic or brand name 
drugs a patient is required to take determines cost effectiveness of SLT compared to 
medical therapy.  
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2.8 Purpose 
2.8.1 Efficacy of SLT 
Previously published studies have reported an average 18-40% reduction post SLT 
treatment57. Latina et al12 conducted a study including 30 patients with uncontrolled OAG 
and showed a 23.5% reduction from baseline at 26 weeks. Melamed et al58studied effects 
of Primary SLT treatment in 45 patients diagnosed with OAG or OHT and found a 30% 
reduction in IOP from baseline up until 18 months post SLT treatment. Overall, the 
effectiveness of SLT has been shown to be successful through previously conducted 
clinical trials11,12.  
2.8.2 Previous Systematic Reviews and Meta-Analyses 
To our knowledge, to date one systematic review59 and three meta-analyses60–62have been 
conducted comparing SLT with topical glaucoma medications. Each study assessed the 
IOP reduction, which was measured in millimeters of mercury (mm Hg).  
Li et al (2015)60 conducted a meta-analysis on studies comparing SLT to topical 
glaucoma medications. In total, they found five studies. The outcomes considered were 
intra-ocular pressure reduction (IOPR), SLT success rate defined as achieving a 20% or 
greater reduction in IOP, and complications associated with SLT. They concluded that 
both SLT and topical medications provided similar reduction in IOP in patients with 
OAG. 
Wong et al(2014)61 performed a meta-analysis comparing SLT with ALT, and SLT with 
topical glaucoma medications, and reported side effects (complications) post SLT. 
Overall, they found that SLT had comparable IOP-lowering effects as medications. 
Peng et al (2014)62 conducted a systematic review and meta-analysis of RCTs comparing 
prostaglandin analogs to SLT. They found three studies that were included in the 
analysis. Overall, their analysis showed that IOP reduction favored prostaglandin 
analogs, with a WMD= [-0.85 mm Hg (95% CI-1.43, -0.27)], and no significant 
heterogeneity (I2=0%, P=0.8) between studies.  
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McAlinder et al (2013)63 conducted a systematic review of studies comparing SLT with 
other treatment methods for glaucoma patients. A subsection of this article directly 
compared SLT versus topical glaucoma medications. Authors summarized results found 
in four studies and found that there was no significant difference between the two 
treatment alternatives.  
Li et al (2015)60, Wong et al (2014)61, and Peng et al (2014)62 conducted their meta-
analyses including the same studies. Overall, two60,61of the meta-analyses showed no 
difference in IOP-lowering effect between SLT and medications-only and one62 study 
favored medications-only (prostaglandin analogs).  
Furthermore, to the best of our knowledge, there has been no systematic review and 
meta-analysis evaluating the effect of SLT as primary, sequential or adjunctive treatment. 
2.8.3 Gap in Knowledge 
The differences in IOP-lowering effect of patients on pharmacotherapy compared to 
patients who received SLT as either sequential, adjunctive, or primary treatment remains 
unknown. This systematic review and meta-analysis is aimed to explore difference in 
treatment strategies. Further, this was the first study evaluating the effect of SLT on the 
reduction in post-operative medications over a period of six to 60 months.  
Moreover, there have been a vast number of studies that have shown SLT to be safe and 
effective. If providing SLT sequentially, adjunctively or as primary treatment is more 
effective at lowering IOP levels than pharmacotherapy, then this could be an impetus for 
ophthalmologists to change current treatment practice for glaucoma patients. Based on 
the literature, cost-analyses have concluded that the majority of patients do not adhere to 
the medication instructions, which can worsen the visual field damage. By providing 
SLT-a cost-effective approach from the patient’s perspective- the visual field damage that 
occurs from noncompliance of the drug regimen can be prevented.  
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2.8.4 Aims and Objectives 
The aim of this thesis was to conduct a systematic review and meta-analysis on the 
efficacy of SLT. The primary objective was to investigate the effect of SLT as primary, 
sequential or adjunctive treatment on the IOP levels and on the number of medications. 
The secondary objective was to assess the reported complications associated with SLT 
treatment. Below are the research questions and the associated hypotheses.  
Primary Research Questions: 
1) Does providing SLT, as primary, sequential, or adjunctive treatment significantly 
reduce the IOP levels compared to topical glaucoma medications? 
Hypothesis: Providing SLT does significantly reduce the IOP levels compared to 
topical glaucoma medications-only treatment. 
2) Does providing SLT as an adjunctive treatment significantly reduce post-
operative topical glaucoma medications? 
Hypothesis: SLT does significantly reduce the post-operative glaucoma 
medications. 
Secondary Research Question (Exploratory): 
3) What are the complications associated with SLT? 
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Chapter 3  
3 Methods 
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 64 
were adhered to (APPENDIX 1). This systematic review was retrospectively registered 
with the Review Registry of Systematic Reviews and Meta-Analyses under the unique 
identifying number reviewregistry185. The methods section contains information on the 
database and grey literature searches, the inclusion and exclusion criteria, screening 
process, data extraction, quality assessment, quantitative measures used for the meta-
analysis, publication bias and how missing data were dealt with.  
3.1 Databases Searched 
MEDLINE (Ovid), EMBASE (Ovid), CINAHL and Cochrane Library were searched from 
January 1997 to July 2016. Six concepts: open-angle glaucoma, prostaglandin analogs, 
beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and selective laser 
trabeculoplasty were used in the search. Articles included from MEDLINE were searched 
by matching the medical subject heading (MeSH) terms with the keyword terms of the two 
concepts ‘glaucoma’ and ‘selective laser trabeculoplasty’ using the Boolean operator AND 
which was then combined with four classes of drugs using the Boolean operator OR. The 
same search strategy was used for EMBASE and CINAHL. In EMBASE, Emtree terms- 
which had the same function as the MeSH terms- were used. For Cochrane library, 
keywords were used since the option to input subject heading terms was not available. 
APPENDIX 2 provides a detailed search strategy for each of the databases.  
3.2 Grey Literature Sources 
Grey literature were searched from the following databases: Web of Science-Core 
Collections, BIOSIS Previews, and Scopus. The same six concepts described above were 
searched. These three databases did not have subject heading options; therefore, keyword 
searches were conducted.  
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3.3 Inclusion and Exclusion Criteria 
Articles studying human subjects over the age of 18 were included. If the age of the 
subjects was not specified, then the use of the word ‘adult’ in the article was assumed to 
be referring to subjects over 18 years of age. The age limit was included in some database 
searches; however, not all of the databases (Cochrane Library, BIOSIS Previews, Web of 
Science-Core Collections and Scopus) had the option of including these limits. English 
written studies published after 1997 were included. 1997 was chosen as the cut off year 
because SLT was invented by Latina and colleagues in 1995 and underwent clinical trials 
beginning in 199712. Randomized clinical trials (RCTs), prospective non-RCTs, cohort, 
retrospective, and observational studies were included. The articles included discussed 
SLT as an intervention; the study either compared SLT directly with medications or 
assessed if SLT reduced the required medications. Studies with sample size of at least 20 
eyes at baseline and follow-up time points were included. Based on ophthalmic literature, 
a sample size of 20 or more eyes is considered to be a good quality study. Studies with 
follow-up data of at least 6 months or greater were included as the literature states that 
SLT could be repeated every six months65; and we wanted to assess the IOP-lowering 
effect after a point where SLT could be repeated, if necessary. Some studies provided a 
follow-up time as a range, for example, 4-6 months. These studies were included in the 
analysis because there was no way of separating the patients who were followed-up for 
four months from those who were followed-up for six months. The study was included in 
the analysis if the medications being compared to SLT were from the following four 
classes: prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, or alpha 
agonists. There was no restriction placed on the country in which the study was 
conducted. The exclusion criteria were any studies that assessed the effect of repeat SLT 
treatment and any patients that had previously undergone glaucoma surgery.  
3.4 Article Screening Process 
Two independent reviewers, Muna Hassan (MH) and Emaad Mohammad (EM), screened 
the articles using EPPI Reviewer 466 (EPPI) (by EPPI-Centre, Social Science Research 
Unit, the Institute of Education, the University of London, UK). The articles were uploaded 
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onto EPPI by converting the document into a RIS file. Once the files were uploaded from 
the different databases and grey literature sources, they were screened for duplicates. We 
selected the option to have EPPI automatically remove the duplicates. Each article was 
assessed again to determine if there were any more duplicates. Once this was done, the 
screening phase was initiated. Throughout the screening process the two screeners, MH 
and EM, held frequent meetings either face-to-face, through Skype or by telephone to 
merge agreements and disagreements and to resolve disagreements at each level of 
screening.   
In total, there were three levels of screening. Level one involved screening only the title of 
the article. Articles evaluating SLT were carried on to level two screening. The articles that 
were included after level two analyzed 20 or more eyes, had six months or greater follow-
up time, and were research articles. If the abstract did not provide enough information to 
answer these three questions then the ‘Unsure’ option was selected. All articles that were 
recorded as ‘Unsure’ were included into the next level of screening. After level one and 
two were screened, the reviewers MH and EM met to discuss any differences in results. 
Level three screening involved reading the entire article. Each reviewer  independently 
reviewed the articles remaining in level three. All of the articles included in the analysis 
either directly compared SLT with medical therapy or looked at SLT as an intervention 
with the aim of examining if SLT reduced the amount of medications. Articles were 
included for meta-analysis after reconciling disagreements. Level 1, 2, and 3 screening 
questions are provided in APPENDIX 3. 
3.4.1 Cohen’s Kappa Statistic 
The Cohen’s kappa statistic was measured to determine the reliability of the data 
collection method. Cohen’s kappa statistic is a measure to determine the level of inter-
rater agreement between categorical items. It is widely used compared to the percentage 
agreement statistic because it takes into account any agreement that may have occurred 
by chance67. As a result, when an assessor wants to determine the inter-rater agreement, 
the percentage agreement statistic is much higher than the kappa statistic.  
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In the article screening process, the kappa statistic represents the extent to which the 
reviewers assign the same inclusion, exclusion, or unsure decision to the same articles. 
This value is calculated using the formula below: 
κ =
Pr⁡(𝑎) − Pr(𝑒)
1 − Pr⁡(𝑒)
 
Pr (a) represents the observed agreement and Pr (e ) represents chance agreement67. The 
kappa statistic produces a value that lies between -1 and +1. A kappa value is often 
accompanied by a p-value and a confidence interval. If the kappa statistic is less than zero 
then that represents less than chance agreement, 0.01- 0.02 represents slight agreement, 
0.21- 0.40 represents fair agreement, 0.41- 0.60 represents moderate agreement, 0.61-
0.80 represents substantial agreement and 0.81- 0.99 represents almost perfect 
agreement68. 
3.5 Outcomes 
3.5.1 IOP Reduction 
One of the primary outcomes was the intra-ocular pressure reduction (IOPR) from 
baseline. The IOPR variable was calculated by subtracting the IOP at each follow-up time 
from the reported IOP at baseline. IOP was measured in millimeters of mercury in all 
included studies. 
3.5.2 Medication Reduction 
The other primary outcome was the reduction in medications. Each drug was defined as 
one medication. For example, if a patient was taking latanoprost and timolol, in two 
separate bottles, this was classified as two medications. If these two drugs were combined 
in one bottle, they counted as two medications. After SLT treatment, if the patient only 
required latanoprost, then this counted as one medication, and the medication reduction in 
this case was one. The medication reduction was assessed as the difference in required 
medications pre-and-post SLT treatment.  
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3.5.3 Complications 
The secondary outcome was an exploratory outcome. We gathered data on any reported 
minor or major complications associated with SLT. The adverse events were reported in a 
list format, and the number of times the complication was reported in other studies were 
tallied and presented in a table.  
3.6 Data Extraction 
All data were extracted from a data extraction sheet, using Excel. The data extraction sheets 
are provided in APPENDIX 4-5.  
3.6.1 Baseline and Follow-up 
Data on author, year of publication, study design, SLT degree, type of glaucoma, baseline 
and follow-up IOP levels, type of medications used, number of patients enrolled and/or 
number of eyes enrolled, and mean age at enrollment were extracted. Additionally, for 
studies that assessed pre-and-post-operative medications, data were gathered on 
medications taken at baseline. Follow-up data were gathered on the number of remaining 
eyes, the IOP levels at each follow-up time, and medications at each follow-up time. The 
extracted data were used to perform descriptive statistics and meta-analysis.  
3.7 Quality Assessment 
The Downs and Black69 checklist was used to assess the methodological quality in the 
RCTs and non-RCTs. This checklist was selected because it was one of the few 
checklists geared towards all types of study designs. The highest possible score was 32. A 
higher score was indicative of better overall quality. Furthermore, the Downs and Black69 
checklist is a 27-item questionnaire that is divided into five sections: Reporting, External 
Validity, Bias, Confounding and Power. The five sections help pinpoint why a study’s 
overall quality may have been low. Each quality assessor, Muna Hassan (MH) and 
Emaad Mohammad (EM), assessed the articles individually. A meeting was held to 
discuss any differences in answers; once a consensus was reached, the assessors decided 
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on a final score for each article. The inter-rater reliability score was calculated using the 
Kappa statistic. APPENDIX 6 provides a copy of the Downs and Black checklist.  
3.8 Quantitative Measures used in the Meta-Analysis 
3.8.1 Meta-Analysis 
Clinical practice is becoming more and more grounded on evidence-based medicine. 
Evidence-based medicine is a systematic, quantitative, preferentially experimental 
approach to using medical information70. Specifically, a meta-analysis is a quantitative 
synthesis of independent studies for the purpose of integrating the findings into one effect 
estimate to determine if an effect exists or if an effect is positive or negative70. The 
outcomes of a meta-analysis may contribute a more precise estimate of the treatment effect 
or risk factor than each of the individual studies. It can also settle controversies arising 
from conflicting studies.  
In this study, a meta-analysis was conducted using STATA 13.071 to determine a pooled 
effect estimate for the IOP reduction between patients that were treated with medications-
only and patients that were given SLT treatment. We also conducted a meta-analysis to 
determine the pooled effect estimate for the reduction in medications for patients with SLT 
treatment. It was assumed that because a meta-analysis is the highest form of evidence-
based medicine, these pooled results would provide a precise and bias-free estimate 
compared to the individual effect estimates.   
3.8.1.1 Effect Measures 
The extracted mean and standard deviation (SD) of the IOP at baseline and end points 
were used to compute the mean IOP reduction (𝐼𝑂𝑃𝑅), percentage of IOP reduction 
(𝐼𝑂𝑃𝑅%), within group standard error (𝑆𝐸𝐼𝑂𝑃𝑅), and standard error of percentage of IOP 
reduction (𝑆𝐸𝐼𝑂𝑃𝑅%) using the equations below
2: 
intbaseline endpoIOPR IOP IOP   
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𝐼𝑂𝑃𝑅% =
𝐼𝑂𝑃𝑅
𝐼𝑂𝑃𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 * 100 
𝑆𝐸𝐼𝑂𝑃𝑅 = √𝑆𝐸𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
2 + 𝑆𝐸𝑒𝑛𝑑𝑝𝑜𝑖𝑛𝑡
2  
𝑆𝐸𝐼𝑂𝑃𝑅% =
𝑆𝐸𝐼𝑂𝑃𝑅
𝐼𝑂𝑃𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 * 100 
The SD of the percentage of IOP reduction (𝑆𝐷𝐼𝑂𝑃𝑅%) was calculated using the formula: 
𝑆𝐷𝐼𝑂𝑃𝑅% = 𝑆𝐸𝐼𝑂𝑃𝑅%×√𝑛 . 
The percentage reduction in medications and the average reduction in medications were 
calculated for the studies that assessed the post-operative reduction in medications. 
The weighted mean difference (WMD) of the percentage of IOP reduction (𝐼𝑂𝑃𝑅%) was 
the effect measure used for the forest plots comparing Sequential SLT and Adjunctive SLT 
with pharmacotherapy. The WMD of the average reduction in medications was the effect 
measure used for the studies that assessed the post-operative reduction in medications.  
WMD was chosen as the effect size because the outcomes being analyzed were continuous 
variables—IOP and medications. Each study was assigned a weight, and this weight was 
multiplied by the IOP percentage reduction or reduction in medications. The values 
computed after these calculations provided the overall WMD. Depending on whether the 
fixed-effect or random-effects model was used, the overall WMD changed.  
3.8.1.2 Heterogeneity 
It is inevitable that effect estimates of independent studies would differ to some degree. 
Heterogeneity tests the amount of variability between the studies being pooled together. 
The variability that occurs because of the differing participants, interventions, or 
outcomes studied is called clinical heterogeneity. The variability that occurs because of 
the study design and risk of bias is called methodological heterogeneity72. Statistical 
heterogeneity results from either clinical, methodological, or both types of heterogeneity. 
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The heterogeneity value tests whether the effect estimates were different from each other 
for reasons other than random chance alone.  
In this study, the null hypothesis for heterogeneity was that the studies shared a common 
effect size73. The values that quantified the inconsistency between the studies were the I2, 
Z-value, and χ2 statistics. The I2 value was made up of the chi-squared value (χ2) minus 
the degree of freedom (k-1), all divided by the chi-squared value (χ2). This value was 
then multiplied by 100 to get a percentage. Higher I2 value was indicative of higher 
between study heterogeneity72. Visually, one could ascertain if there was heterogeneity if 
the confidence intervals of the effect estimates between the studies did not overlap. If the 
I2 is less than 40% then heterogeneity is not important, I2 between 30% and 60% may 
represent moderate heterogeneity, I2 between 50% and 90% may represent substantial 
heterogeneity and I2 between 75% and 100% represents substantial heterogeneity72 
3.8.1.3 Random-Effects and Fixed-Effect Models 
In the fixed-effect model, it is assumed that there is only one true effect size for all of the 
studies, and the combined effect is the estimate of this common effect size72. This model 
assumes homogeneity, meaning that there are no differences in the study population; 
subject selection criteria and applied treatments. In a fixed-effect model, if the sample 
size is large enough, the standard error will approach zero.  
On the other hand, in the random-effects model, it assumes that the true effect varies 
from study to study. Each study is estimating a different effect size. The weights assigned 
under the random-effects model are more evenly distributed and unlike the fixed effect 
model, large studies do not dominate and smaller studies do not get overlooked 73.  In the 
random effects model, the studies are weighted according to the inverse of their variance 
and the heterogeneity parameter70. Often, the random-effects model is used to interpret 
the summary of effects when the heterogeneity is significant. In this study, effect 
estimates from the random-effects model were used when the statistical heterogeneity 
exceeded I2=50%. 
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3.9 Subgroup Analysis 
3.9.1 SLT versus Medications Studies 
Subgroup analyses were conducted using the SLT versus medications studies to 
determine if there was a difference in results based on the timing that the SLT procedure 
was provided. The timing of the SLT procedure was separated into three groups: primary 
treatment, sequential treatment and adjunctive treatment.  Primary SLT referred to when 
a patient was newly diagnosed with glaucoma and was receiving SLT on treatment naïve 
eyes. Sequential SLT was when a patient initially was on medical treatment, was washed-
out of the medications for about 4-5 weeks, and then received SLT treatment. Adjunctive 
SLT referred to when a patient was on pharmacotherapy treatment, and was provided 
SLT while continuing with their medical treatment. 
3.9.2 Adjunctive SLT Studies 
Subgroup analyses were conducted using the Adjunctive SLT studies that examined the 
post-operative reduction in medications. A subgroup analysis was conducted based on the 
SLT degree. The purpose was to determine if a difference in the results occurred based on 
the SLT degree. SLT is a laser procedure that is performed on the 360 degree trabecular 
meshwork (TM) where the fluid drains from the eye. Ophthalmologists perform SLT at 
varying degrees. Some ophthalmologists perform SLT on the entire TM (360 degrees), 
while others perform on 270, 180, or 90 degrees of the TM. For this analysis, we 
stratified the data into two groups: one group received 180 degrees of laser treatment and 
the other group received 360 degrees of laser treatment.  
A subgroup analysis was also conducted based on the study design. The purpose was to 
determine if the design of the study had an effect on the results. The studies were stratified 
into two groups: those that were randomized clinical trials (RCTs) and those that were not 
RCTs. 
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3.10 Sensitivity Analysis 
A sensitivity analysis was conducted to examine the robustness of the results by assessing 
to what extent the results are affected by a change in methods or assumptions74. In the 
primary analysis for the studies comparing SLT with medications, all studies were 
included irrespective of the quality. The sensitivity analysis was conducted to determine 
if removing the abstracts and non-RCT studies, which had the lowest overall quality, 
made an impact on the results. In the Adjunctive SLT studies that assessed the pre-and-
post-operative medications, we removed the abstracts that were included in the primary 
analysis to determine how much of an effect they played on the results. The reason we 
removed the abstracts was because they had a lower overall quality score compared to the 
full studies. After performing the sensitivity analysis, if the results did not change from 
the primary analysis, then it was concluded that factors had little or no influence on the 
conclusions, which means that the results are robust74 
3.11 Publication Bias 
The purpose of a meta-analysis is to find and synthesize all the studies that meet the 
specified inclusion and exclusion criteria so that the most accurate summary effect 
estimates are presented. Often times publication bias occurs because the authors do not 
want to publish non-significant results70,72. Larger studies with significant results are 
more likely to be published than smaller studies with non-significant results70. 
Publication bias can also occur because publishers  may not want to publish non-
randomized or uninteresting results70. Another reason for missing studies may be the 
inclusion criteria that were created for the systematic review. Some studies could be 
missed through the database searching or the article screening process.  
In order to assess publication bias, a funnel plot was created with Review Manager 
(RevMan)75. WMD was used as the unit of measure because the variable being analyzed 
was continuous. The standard error of the WMD was calculated and plotted on the y-axis 
of the graph and the WMD was plotted on the x-axis of the graph. If publication bias does 
not exist, the plot is expected to have a symmetric inverted funnel shape70.  The top of the 
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funnel plot is occupied by larger studies with an effect size that is closer to the mean effect 
size. The smaller studies occupy the bottom of the funnel plot because they usually have 
larger standard errors and tend to spread across a wider range of effect estimate values. 
Even though funnel plot asymmetry could be due to publication bias, there may also be 
other reasons causing the asymmetry including high heterogeneity, differences in 
methodological quality, language bias, and time-lag bias70.  
3.12 Missing Data 
The Cochrane Handbook for Systematic Reviews of Interventions (2008)72 was used to 
calculate values that were not directly reported in the articles. Based on the data extraction 
sheets that we created, not all of the values were directly provided by the articles. Standard 
deviations that were not reported on the reduction of IOP were calculated either from the 
reported p-values or range72. Studies that had important values left blank were included in 
the charts, but excluded in the forest plots.  
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Chapter 4  
4 Results 
4.1 Study Characteristics 
4.1.1 SLT versus Medications Studies 
Of the 31 studies,  776–82 articles compared SLT with medications. Baseline 
characteristics of these 7 studies are reported in Table 1. In total, 577,78,80–82 out of the 7 
studies conducted SLT at 360 degrees, one76 study performed 180 degrees, and one79 
study reported results for 90, 180 and 360 degrees. All studies had the SLT laser initially 
set at 0.8mJ with an increase or decrease of 0.1mJ.  Six77–82 of the included studies were 
randomized controlled trials (RCT).  
Three77,78,81 studies provided SLT as adjunctive treatment with medical therapy. 
Three79,80,82 studies provided SLT sequentially after about a 4 week wash-out period, and 
one76 study provided SLT as primary and as sequential therapy. Four76,79,80,82 studies 
compared SLT directly with a prostaglandin analog, and three76,79,80 studies compared 
SLT with latanoprost. Three77,78,81 studies compared SLT with a combination of medical 
drugs from all four classes of drugs. All additional information are provided in Table 2
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Table 1: Baseline Characteristics of Included Studies Comparing SLT with Medications 
Author, 
Year of 
Publication 
SLT Timing Degree/(Type of 
Glaucoma) 
Study 
Design 
N (Eyes)  SLT 
Group 
Mean 
Age(SD) 
Medications 
Group Mean 
Age(SD) 
SLT Group Mean 
IOP(SD) 
Medications 
Group Mean 
IOP(SD) 
Katz et al, 
201282 
Sequential 360°(POAG/OHT) RCT 127 53.5 (14.2) 53.5 (14.2) 25 (2.2) 24.5(2.2) 
Lai et al, 
200478 
Adjunctive 360°(POAG/OHT) RCT 
 
58 51.9 (14.7) 51.9 (14.7) 26.8 (5.6) 26.2 (4.2) 
Lee et al, 
201477 
Adjunctive 360° 
(POAG) 
RCT 41 66.5(13.6) 65.5(12.7) 15.8(2.7) 14.5(2.5) 
McIlraith et 
al, 200676 
Primary 180° 
(OAG) 
Pro non-
RCT 
100 62(11) 63(11) 
 
26 (4.3) 24.6(3.7) 
Sequential 180° 
(OAG) 
Pro non-
RCT 
87 NR 26.5(4.5) 
Nagar, 
200579 
Sequential 90° , 180°  and 
360°(OAG/OHT) 
RCT 167 63(17) 63(17) 90  °  24.5(NR) 29.2(NR) 
180 °  29.7(NR) 
360 °  30.2(NR) 
Nagar, 
200980 
Sequential 360° 
(POAG/OHT) 
RCT 40 66.4(NR) 66.4(NR) 26.1(4) 22.8(4.5) 
Tan et al, 
201581 
Adjunctive  360° 
(POAG/OHT) 
RCT 156 55.5(2.7) 55.5(2.7) 20.76(3.3) 20.54(3) 
RCT: Randomized Control Trial; Pro non-RCT:Prospective Non-RCT; NR:Not Reported; N:Number of Eyes; SD: Standard Deviation;  
POAG: Primary Open-angle Glaucoma; OHT:Ocular Hypertension; OAG: Open-angle Glaucoma; SLT: Selective laser trabeculoplasy; IOP: Intra-ocular pressure 
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Table 2: SLT Characteristics of Included Studies Comparing SLT with Medications 
Author, Year of 
Publication 
Medications Directly 
Before SLT 
Medications Directly After 
SLT 
Laser Spots, Contiguous 
versus Spaced, Degree 
Medications Used 
Katz et al, 201282 - - 100 laser spots over 360° Prostaglandin analogs 
Lai et al, 200478 One drop of 1% 
apraclonidine 1 hour 
prior to treatment 
One drop of 1% 
apraclonidine and 1% 
prednisolone acetate 
100 non-overlapping laser spots 
over 360° 
Beta-blockers, pilocarpine, 
dorzolamide, and latanoprost 
Lee et al, 201477 - One drop of Alphagan and 
dexamethasone 0.1% and 
neomycin 0.5% twice a day 
for 1 day 
Single burst mode through 360° 
of trabecular meshwork 
Prostaglandin analogs or 
beta-blockers, followed by 
carbonic anhydrase 
inhibitors or alpha 
adrenergic agonist, then 
pilocarpine 
McIlraith et al, 
200676 
Brimonidine 0.2% and 
pilocarpine 1% 1 hour 
before treatment 
One drop of brimonidine 
0.2% and either prednisolone 
acetate 1% or ketorolac 0.5%  
immediately after therapy 
and Prednisolone acetate 1% 
or ketorolac 1% four times a 
day for 5 days 
50(SD: 5) contiguous laser 
spots over 180° 
Latanoprost 
Nagar et al, 
200579 
One drop of 
amethocaine 1%  
Either dexamethasone 0.1% 
eye drops of ketorolac eye 
drops for four times a day for 
5 days 
90°: 25-30 laser spots,  
180°: 48-53 laser spots,  
360°: 93-102 laser spots 
Latanoprost 
Nagar et al, 
200980 
One drop of 
amethocaine 1%  
Non-steroidal anti-
inflammatory drops 
(ketorolac tromethamine) 
four times a day for 5 days 
100(SD: 5) non-overlapping 
spots over 360° 
Latanoprost 
Tan et al, 201581 - - 360° Prostaglandin analogs, beta-
blockers, carbonic anhydrase 
inhibitors and alpha-agonists 
SLT: Selective laser trabeculoplasty; SD: Standard Deviation 
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4.1.2 Adjunctive SLT Studies 
The baseline characteristics of the Adjunctive SLT studies are provided in Table 3. Data 
gathered included author, year of publication, type of glaucoma, study design, number of eyes, 
-mean age, mean number of medications, and the IOP levels at baseline. Of the 31 studies that 
were finalized after level three screening, 2777,78,81,83–105 of the studies reported data on number 
of medications pre-and-post SLT. Out of the 27 studies, 1677,81,83,87,89–91,95–97,99–102,105,106studies 
reported data for 360 degrees of SLT treatment, 1284–86,88,92–94,98,100,103,104,106 studies reported 
data on 180 degrees of SLT treatment, two105,106 studies reported data on 270 degrees. 
Nine77,78,81,84,86,94,102,104,105 studies were RCTS, one85 was a partial RCT, as only patients 
receiving their first laser therapy were randomly assigned. Eight89,90,95,96,98,100,103,106 studies 
were retrospective chart reviews, three83,91,99 studies were observational studies, and two87,97 
studies were non-randomized clinical trials. There were a total of 1,742 eyes included in the 
analysis. Where the number of eyes were not reported, the number of patients were included, 
and it was assumed that there was an eye from each patient included in the analysis. The 
number of medications at baseline ranged from an average of 1.398 to 3.2381  medications. The 
IOP levels at baseline ranged from 14.3mm Hg99 to 26.8mm Hg78. Five81,89,98,104,105 of the 
studies included were abstract only. Four85–87,94 studies were conducted in Canada, 
nine88,90,92,95,96,98,100,101,106 studies were conducted in USA and the remaining 
1477,78,81,83,84,89,91,93,97,99,102–105 studies were conducted outside of North America. Additional 
information regarding the SLT characteristics can be found in Table 4, and additional 
information regarding types of medications used can be found in Table 5. 
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Table 3: Baseline Characteristics of Studies Evaluating Adjunctive SLT 
Author, Year of 
Publication 
Type of 
Glaucoma 
Study Design N 
(Eyes) 
Mean Age 
(SD) 
Mean 
Medication 
(SD) 
Mean 
IOP (SD) 
Abdelrahman et al. 
201283 
POAG Prospective (SLT) 65 53.2(15) 2.25(0.97) 18.29(NR) 
Babighian et al. 
201084 
POAG RCT (ELT vs 
SLT) 
15 67(3.2) 2.2(0.7) 23.9(0.9) 
Birt, 200785 OAG Partially RCT* 
(ALT vs SLT) 
30 64(13.9) 2.9(1.2) 22.9(4.2) 
Bovell et al. 201186 OAG RCT (ALT vs 
SLT) 
89  
 
69.7 (10.5) 2.6 (1.2) 
 
23.8(4.8) 
Bruen et al.201287 OAG/OHT Non-randomized 
cohort study 
(SLT) 
74 
 
 
71 (10) 2.0(1.0) 21.5(0.5) 
Francis et al. 200588 OAG Non-RCT (SLT) 66 65.4(8.2) 2.8(1.1) NR 
Giocanti-Auregan et 
al. 201489 (abstract) 
OAG Retrospective 
(SLT) 
46 NR 1.6(0.8) 22.8(3.8) 
Greninger et al. 
2014106 
OAG Retrospective 
Case Series (SLT) 
110 74.1(10.5) 2.6(1.07) 18.7(NR) 
Habib et al. 201390 NTG Retrospective 
Review (SLT) 
104 70(10) 2.03(1.01) 19.6(3.7) 
Hirneib et al. 2013 91 
 
OAG Observational 
(SLT) 
68 
 
68.5(13.3) 2.38(1.1) 18.1(5.2) 
POAG Observational 
(SLT) 
45 
 
NR NR 17.8(4.6) 
Juzych et al. 200492 Chronic 
OAG 
RCR (SLT vs 
ALT) 
41  71.9(8.8) 2.5(1.3) 23.9(2.6) 
Kara et al.2013 93 POAG Retrospective 
case series (SLT) 
48 
 
63(10) 1.9(1) 22.7(2.1) 
Kent et al.201594 PXG RCT (SLT vs 
ALT) 
45 72.9(9.8) NR 23.1(4.2) 
Khouri et al. 2014a 95 OAG Retrospective 
Review (1st SLT 
vs repeat SLT) 
46 
 
73(9) 1.7(0.9) 19.7(2.3) 
Khouri et al. 2014b96 OAG Retrospective 
Review (1st SLT 
vs repeat SLT) 
51 NR 1.57(0.83) 19.9(3.2) 
Koucheki & 
Hashemi 201297 
 
OAG Prospective 
nonrandomized 
interventional 
study(SLT) 
136 62.1(13.1) 2.3(0.7) 22(NR) 
Lai et al. 200478 OAG/ 
OHT 
RCT (SLT vs 
Meds) 
58 51.9(14.7) - 26.8(5.6) 
Leon et al. 200598 
(abstract) 
OAG Retrospective 
(SLT) 
49 NR 1.3(NR) - 
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Table 3: Baseline Characteristics of Studies Evaluating Adjunctive SLT (Continued) 
Author, Year of 
Publication 
Type of 
Glaucoma 
Study Design N (Eyes) Mean Age 
(SD) 
 
Mean 
Medication 
(SD) 
Mean 
IOP (SD) 
Lee et al. 201477 OAG RCT (SLT vs 
Meds) 
41 66.5(13.6) 2.3(1.1) 15.8(2.7) 
Lee et al. 201599 NTG Prospective 
Cohort (SLT) 
41 64.7(11.9) 1.5(0.8) 14.3(3.4) 
Lowry et al. 
2016100 
OAG Retrospective 
Interventional 
Comparative Case 
Series (ALT vs 
SLT) 
100 75.54(10.6) 2.62(1.1) 18.5(4.2) 
Rebenitsch et al. 
2013101 
OAG RCR(SLT) 111 70.5(10.9) 1.5(1.26) 18.9(4.5) 
Russo et al. 
2009102 
Chronic 
OAG 
RCT (SLT vs 
ALT) 
60 57.8(5.3) 2.3(1.3) 22.7(1.2) 
Schlote & 
Kynigopoulos, 
2016103 
Advanced 
OAG 
Retrospective 
Review (early vs 
advanced OAG) 
36 73.8(9.7) 1.9(1.0) 22.1(4.1) 
Tan et al.201581 
(abstract) 
OAG RCT(SLT vs 
Meds) 
78 55.5(2.6) 3.23(0.4) 20.7 (3.3) 
Zaninetti & 
Ravinet, 2008104 
(abstract) 
OAG RCT(SLT) 67 69(8) 1.44(NR) 
*drops/patient 
19.2(4.7) 
Zhang et al. 
2015105 (abstract)  
OAG RCT(270 
degrees) 
67 NR 2.3(0.5) NR 
OAG RCT(360 
degrees) 
67 NR 2.1(0.4) NR 
*Partially RCT85: Patients that had undergone previous 360 degree ALT treatment, were assigned to receive SLT. Patients 
with no previous laser therapy were randomized by means of a coin toss. 
*In this study104, the medications were measured as the number of drops on average per patient 
RCR: Retrospective Chart Review; RCT: Randomized Clinical Trial; OAG: Open-angle glaucoma; POAG: Primary Open-
angle Glaucoma; PXG: Pseudoexfoliative Glaucoma; NTG: Normal tension glaucoma; SLT: Selective laser trabeculoplasty; 
ALT: argon laser trabeculoplasty; ELT: Excimer laser trabeculoplasty; Meds: Medications; NR: Not reported; N: Number of 
eyes; vs: versus; SD: Standard deviation 
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Table 4: SLT Characteristics of Studies Evaluating Adjunctive SLT 
Author, Year of 
Publication 
Degrees Clock-hour Laser spots Contiguous versus 
Spaced Spots 
Abdelrahman et al. 
201283 
360 - 100 Contiguous 
(adjacent) 
Babighian et al. 201084 180 - 50 Adjacent 
Birt, 200785 180 Inferior 45-55 - 
Bovell et al. 201186 180 - 50 - 
Bruen et al.201287 360 - 60 Non-overlapping 
Francis et al. 200588 180 Inferior 55 (range: 49-70) - 
Giocanti-Auregan et 
al, 201489 (abstract) 
360 Centered on 
trabecular 
meshwork 
100 (SD:10) Non-overlapping 
Greninger et al. 
2014106 
180, 270, 
360 
- 94.3 (SD:49) - 
Habib et al. 201390 360 - 102 (SD:15.2) - 
Hirneib et al. 2013 91 
 
360 - - Non-overlapping 
Juzych et al. 200492 180 Nasal 
trabecular 
meshwork 
50-55 Non-overlapping 
spots, adjacent 
Kara et al.2013 93 180 Inferior or 
nasal 
- Contiguous 
Kent et al. 201594 180 Inferior or 
superior 
50 applications - 
Khouri et al. 2014a 95 360 - - - 
Khouri et al. 2014b96 360 - - Non-contiguous 
Koucheki & Hashemi 
201297 
360 Mid-height of 
trabecular 
meshwork 
100 Non-overlapping  
Leon et al. 200598 
(abstract) 
360 - - - 
Lee et al.201477 360 - 121.8 (SD:30) - 
Lee et al.201599 360 - 191 (SD:27.3) - 
Lowry et al. 2016100 180 to 
360  
- 95.8(SD:50.7) - 
Rebenitsch et al. 
2013101 
360 - - - 
Russo et al. 2009102 360 - 60 Non-overlapping 
Schlote & 
Kynigopoulos, 2016103 
180 Inferior 50-70 Adjacent, non-
overlapping 
Tan et al. 201581 
(abstract) 
360 - - - 
Zaninetti & Ravinet, 
2008104 (abstract) 
180 Inferior - - 
Zhang et al, 2015105 
(abstract) 
270 or 
360 
- - - 
SD: Standard deviation 
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Table 5: Medication Details of Studies Evaluating Adjunctive SLT 
Author, Year of 
Publication 
Medications directly 
Before SLT 
Medications Directly 
After SLT 
Medications provided 
for Glaucoma 
Treatment 
Abdelrahman et al, 
201283 
A drop of miotic 
(pilocarpine nitrate 2%) 
and brimonidine tartrate 
0.2% (Alphagan) 
Prednisolone acetate 
(1%) drops 
- 
Babighian et al, 
201084 
Topical anesthesia with 
0.4% benozinate in a 
single dose solution and 
1% methylcellulose on 
the cornea 
 
Topical steroid 
antibiotic association 
with tobramycin and 
dexamethasone eye 
drops four times a day 
for 14 days 
53% Beta-blockers, 25% 
alpha-agonists, 33% 
CAI(topical), 13% CAI 
(oral), 93% PGA 
Birt, 200785 One drop of 
brimonidine 0.2%  
 
 
Fluoromethalone 0.1% 
(Allergan) drops four 
times daily for 5 days 
86% on Beta-blockers, 
36% on CAI, 43% on 
Alpha-agonist, 83% on 
PGA, 6% on Pilocarpine 
Bovell et al, 201186 Apraclonidine or 
brimonidine tartrate 
0.2%  
Topical prednisolone 
acetate 1% for 5 days 
53% PGA, 65% Beta-
blockers, 31% Alpha-
agonist, 62% CAI, 38% 
Pilocarpine, 78% 
Combination 
Bruen et al,201287 - - PGA, B-blockers 
Francis et al, 200588 - One drop of brimonidine 
tartrate 0.2% and 
prednisolone acetate 1% 
three times daily for 4 
days 
Beta-blockers, CAI, 
Alpha-agonist, PGAs, 
pilocarpine(10 on 1 
medication, 18 on 2, 14 
on 3, 24 on 4 
medications) 
Greninger et al, 
2014106 
1 drop of topical 
proparacaine 
hydrochloride and 
apraclonidine 
hydrochloride 0.5% 
1 drop of apraclonidine 
hydrochloride 0.5% 
- 
Hirneib et al, 2013 91 
 
Tetracaine (0.5% used 
for anaesthesia 
Flurbiprofene (0.03%) 
four times a day for 3 
days 
- 
Juzych et al, 200492 Topical tetracaine or 
proparacaine 
hydrochloride was used 
as anesthesia, eyes 
pretreated with 
apraclonidine 1.0% 
Topical steroids 4 times 
daily for one week 
- 
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Table 5: Medication Details of Studies Evaluating Adjunctive SLT (Continued) 
Author, Year of 
Publication 
Medications directly 
Before SLT 
Medications 
Directly After SLT 
Medications provided 
for glaucoma 
treatment 
Kara et al,2013 93 1 drop of topical 
proparacaine 
hydrochloride 0.5% 
1 drop of 
brimonidine (0.2%) 
and fluorometholong 
(Flarex) eye drops 4 
times a day for one 
week 
- 
Kent et al, 201594 1 drop of brimonidine 
0.2% and pilocarpine 
1%  
- - 
Koucheki & Hashemi 
201297 
 
1 drop of tetracaine 
(0.5%) in each eye 
Flourometholone 
(0.1%) twice a day 
for 3 days 
75% on PGA 
Lai et al. 200478 One drop of 1% 
apraclonidine 1 hour 
prior to treatment 
One drop of 1% 
apraclonidine and 
1% prednisolone 
acetate 
Beta-blockers, 
Pilocarpine, 
Dorzolamide, and 
Latanoprost 
Lee et al.201477 - One drop of 
Alphagan and 
dexamethasone 0.1% 
and neomycin 0.5% 
twice a day for 1 day 
PGA or Beta-blockers, 
followed by CAIs or 
Alpha-agonist, then 
Pilocarpine 
Lee et al. 201599 - A drop of 
brimonidine tartrate; 
dexamethasone 0.1% 
and neomycin 0.5% 
combination eye 
drop used twice a 
day for 1 day 
Alpha-agonists or PGAs 
followed by topical, 
CAIs, then Beta-
blockers 
Lowry et al, 2016100 1 drop of topical 
proparacaine and 
iopidine 0.5% 
1 drop of iopidine 
0.5% 
- 
Russo et al, 2009102 - 1 drop of topical 
indomethacin 0.1% 4 
times daily for 1 
week 
- 
Schlote & 
Kynigopoulos, 
2016103 
Topical anesthesia with 
tetracaine eye drops, 
and eyes were 
pretreated with 
apraclonidine 1.0% 
Topical non-steroidal 
anti-inflammatory 
eye drops 4 times a 
day for 1 week 
- 
PGA: Prostaglandin analogs; CAI: Carbonic Anhydrase Inhibitors; SLT: Selective laser trabeculoplasty 
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4.2 Study Selection 
4.2.1 Screening 
EPPI Reviewer 4.0(by EPPI-Centre, Social Science Research Unit, the Institute of Education, 
the University of London, UK), was used to screen the articles. Search strategies were used to 
gather articles from the journal databases MEDLINE (Ovid), EMBASE (Ovid), CINAHL, 
Cochrane Library and the grey literature databases including Web of Science-Core Collections, 
BIOSIS Previews, and Scopus. There were 1,138 articles identified from the journal databases 
and 375 articles included from the grey literature sources. One-hundred and forty eight 
duplicates were removed by EPPI Reviewer 4.0 and another 48 were manually removed by the 
reviewer (MH). A total of 1,317 articles were included for screening.  
After screening, a total of 99 articles were included. After manually reviewing 99 articles, 31 
articles met the inclusion and exclusion criteria and were included for quantitative and 
qualitative analysis. Figure 1 provides a PRISMA flow diagram outlining the screening process 
and the reasons for exclusion at each level. 
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Figure 1: PRISMA Flow Diagram 
 
Abbreviations: SLT= Selective laser trabeculoplasty, OAG= Open angle glaucoma, MA= Meta-analysis, SR= 
Systematic review 
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4.2.2 Inter-rater Agreement 
At each level of screening the inter-rater reliability was calculated using the kappa 
statistic. In the title and abstract screening, the percentage agreement was 89%, and the 
kappa score between the two reviewers (MH and EM) was 0.53. According to the kappa 
statistics guidelines, this was considered moderate agreement. Most of the differences in 
the agreement were due to articles that EM marked as ‘unsure’ and MH marked as 
‘exclude’. For the full text screening, the percentage agreement was 91% and the kappa 
score was 0.82, which was considered almost perfect agreement. 
4.3 Quality Assessment 
4.3.1 Downs and Black Risk of Bias Assessment 
The score for reporting information sufficiently was 7.3 out of 10, on average. The 
overall score for external validity, which addressed issues of generalizability, was 2.3 out 
of 3, on average. The potential bias in the measurement of the intervention and the 
outcome was 4.4 out of 7, on average. The average confounding score was 2.2 out of 6. 
The score for the power of the study was 0.83 out of 5 on average. The reason this value 
was low was because the majority of the studies did not report on the probability of 
rejecting a false null hypothesis, also referred to as the power of the study, resulting in a 
score of 0. The quality scores were higher in the RCT studies with an overall score of 
21.6 compared to 17.03 in all the studies. Table 6 provides a tabular form of the quality 
assessment results for the clinical trials and the observational studies included in the 
analysis.  
The kappa statistic was used to assess the level of agreement between the individual 
ratings of each assessor (MH and EM). Tables 7 provides a detailed summary of the 
percentage agreement and the kappa statistic agreement for each study. 
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Table 6: Downs and Black Quality Assessment Average Score for each Category 
Quality Index Overall Quality Score (31 
studies including RCTs and 
non-RCTs) 
RCTs(12 studies) 
Average 
Score 
Range Average 
Score 
Range 
Reporting 7.3 5-10 7.25 5-10 
External Validity 2.3 0-3 2.08 0-3 
Bias 4.4 1-6 8.1 1-6 
Confounding 2.2 0-5 2.5 0-5 
Power 0.83 0-5 1.67 0-5 
Total 17.03 (53%)  21.6 (68%)  
Higher values are indicative of better performance in that category 
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Table 7: Kappa Statistics Computed for Individual Studies 
Author, Year of 
Publication 
% Agreement  Kappa Statistic (SE) 
Abdelrahman et al, 201283 74.0% 0.49(0.17) 
Babighian et al, 201084 66.67% 0.31(0.15) 
Birt, 200785 55.6% 0.08(0.19) 
Bovell et al, 201186 70.3% 0.30(0.14) 
Bruen et al,201287 77.78% 0.52(0.19) 
Francis et al, 200588 75% 0.44(0.19) 
Giocanti-Auregan et al, 
201489 
70.3% 0.42(0.17) 
Greninger et al, 2014106 66.67% 0.31(0.19) 
Habib et al, 201390 77.78% 0.55(0.19) 
Hirneib et al, 2013 91 77.78% 0.56(0.17) 
Juzych et al, 200492 85.19% 0.69(0.19) 
Kara et al,2013 93 66.6% 0.32(0.17) 
Katz et al, 201282 88.89% 0.72(0.19) 
Kent et al, 201594 70.37% 0.41(0.31) 
Khouri et al, 2014a95 88.89% 0.75(0.19) 
Khouri et al, 2014b96 92.59% 0.83(0.19) 
Koucheki & Hashemi, 
201297 
77.78% 0.47(0.19) 
Lai et al, 200478 88.89% 0.75(0.19) 
Leon et al, 200598 88.89% 0.74(0.19) 
Lee et al, 201477 70.37% 0.32(0.17) 
Lee et al, 201599 92.59% 0.84(0.19) 
Lowry et al, 2016100 81.48% 0.62(0.18) 
McIlraith et al, 200676 77.78% 0.47(0.19) 
Nagar et al, 200579 85.19% 0.72(0.17) 
Nagar et al, 200980 81.48% 0.64(0.17) 
Rebenitsch et al, 2013101 92.59% 0.83(0.19) 
Russo et al, 2009102 81.48% 0.58(0.19) 
Schlote & Kynigopoulos, 
2016103 
74.07% 0.40(0.19) 
Tan et al, 201581 92.59% 0.82(0.19) 
Zaninetti & Ravinet, 
2008104 
92.59% 0.82(0.19) 
Zhang et al, 2015105 92.59% 0.84(0.19) 
Higher numbers are indicative of better agreement 
SE: Standard Error 
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4.4 Publication bias 
Figure 2 depicts the funnel plot for the studies comparing SLT with medications. If the 
fixed-effect estimate is true and no bias is present, then the dotted line triangle is centered 
on a fixed effect summary estimate and extends 1.96 standard errors either side and 
includes about 95% of the studies72. The WMD of the percentage reduction in IOP was 
plotted on the x-axis and the standard error of the WMD of the percentage reduction in 
IOP was plotted on the y-axis. The standard error on the y-axis decreased as we went up 
the funnel plot.  None of the studies were plotted inside the pseudo 95% fixed estimate, 
suggesting that heterogeneity may be present. All of the studies were plotted near the 
middle and top of the funnel plot.  
Figure 3 shows the funnel plot for the Adjunctive SLT studies examining pre-and-post-
operative medications. The WMD of the reduction in medications was plotted on the x-
axis and the standard error of the WMD of the reduction in medications was plotted on 
the y-axis. The majority of the studies were located to the right of the average effect 
estimate (the central line) and 8 of the 15 studies were located outside of the expected 
pseudo 95% interval, suggesting heterogeneity may be present.  The bottom left corner of 
the funnel plot was empty, suggesting that smaller studies may not have been published. 
Although publication bias may be one reason for the asymmetry, there are several other 
reasons for funnel plot asymmetry which include: high heterogeneity, language bias, and 
availability bias. 
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Figure 2: Funnel Plot for Studies Evaluating SLT versus Medications
 
The standard error (SE) of the mean difference (MD) in the intra-ocular pressure 
percentage reduction is plotted on the y-axis. The MD of the intra-ocular pressure 
percentage reduction is plotted on the x-axis. N=7.  
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Figure 3: Funnel Plot for Studies Evaluating SLT as an Adjunctive Treatment
 
 
The standard error (SE) of the mean difference (MD) in the reduction in medications is 
plotted on the y-axis. The MD of the reduction in medications is plotted on the x-axis. 
N=17.  
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4.5 Impact on Intra-ocular Pressure Reduction (IOPR) 
4.5.1 IOPR after SLT 
Thirty studies provided data on the IOP reduction after SLT. Table 8 lists twenty-six of 
the studies that provided SLT adjunctively with medications, and three79,80,82 studies that 
provided SLT sequentially after about a 4-5 weeks wash-out of medications, and one76 
study that provided SLT as primary and sequential treatment. Data were presented on the 
follow-up time, number of eyes at each follow-up time, the percentage IOP reduction 
(𝐼𝑂𝑃𝑅%), and the standard error of the percentage IOP reduction (𝑆𝐸𝐼𝑂𝑃𝑅%).  In total there 
were 2561,76,78–84,87,90–98,100,102,103,105,106 studies that reported data on 6-9 months, 
2276,78,79,82–87,89,90,92,93,95,97,99–103,106 studies on 12 months follow-up, six83,84,90,95,97,99 studies 
on 18 months of follow-up, nine84,86,90,92,95,99,100,104,106 studies on 24 months of follow-up, 
two86,90 studies reported data on 36 months, two86,92 studies reported on 48 months and 
three86,89,92 studies reported data on 60 months or greater.  
The percentage IOP reduction averaged 21.3% (range: 14.3% to 40.4%) at 6-9 months, 
22.4% (range: 11.8% to 43.7%) at 12 months, 17.1% (range: 11% to 20.9%) at 18 
months, 17.2% (range: 11% to 23.5%) at 24 months, and 28.3% (range: 17.5% to 34.2%) 
at 36 months or greater.  
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Table 8:Intra-ocular Pressure Percentage Reduction Post SLT 
Author, Year of 
Publication 
Follow-up 
(months) 
N (eyes) IOP 
Percentage 
Reduction 
SE_IOPR% 
Abdelrahman et al, 
201283 
6  65 21.8% .051 
12  65 23.4% .052 
18  65 19.6% .049 
Babighian et al, 201084 6  15 19.6% .102 
9  15 18.4% .100 
12  15 18.8% .100 
18  15 20.9% .104 
24  15 20.9% .104 
Birt, 200785 12  30 22.7% .076 
Bovell et al, 201186 12 78 25.2% .049 
24  79 23.5% .047 
36  75 28.2% .052 
48  72 29.4% .053 
60  64 31.1% .058 
Bruen et al, 201287 6  56 17.67% .051 
12  51 21.7% .058 
Giocanti-Auregan et 
al, 2014 (abstract)89 
12  NR 29.4% - 
144  NR 34.2% - 
Greninger et al, 
2014106 
6  84 14.5% .038 
12  80 11.8% .036 
24  49 15.6% .051 
Habib et al, 201390 8  79 20.5% .180 
12  75 18% .180 
18  65 17.7% .180 
24  24 12.1% .020 
36  18 17.5% .030 
Hirneib et al, 201391 6 (OAG) 68 19.3% .048 
6 (POAG) 45 19.3% .048 
Juzych et al, 200492 6  37 14.3% .057 
12  32 18.1% .068 
24 29 23.4% .078 
36  25 23.4% .078 
48  21 21.2% .089 
60  20 27.1% .099 
Kara et al, 201393 6  (POAG) 48 19.8% .057 
12 (POAG) 48 19.3% .056 
6 (PXG) 37 25.8% .071 
12(PXG) 37 27.2% .073 
Katz et al, 201282 4-6 38 22.8% .068 
9-12 29 25.0% .080 
Kent et al, 201594 6 NR 29.8% - 
Khouri et al, 2014a95 8  39 21.3% .065 
12 38 19.2% .064 
18 36 17.7% .064 
24  28 12.2% .062 
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Table 8: Intra-ocular Pressure Percentage Reduction Post SLT (Continued) 
Author, Year of 
Publication 
Follow-up (months) N (eyes) IOP 
Percentage 
Reduction 
SE_IOPR% 
Khouri et al, 2014b96 8  42 20.8% .062 
12 43 16.5% .056 
Koucheki & Hashemi, 
201297 
6  121 20.0% .036 
12  127 18.2% .034 
18  78 17.3% .042 
Lai et al, 200478 6  24 29.4% .084 
12 24 29.4% .084 
60 24 32.1% .086 
Leon et al, 2005 
(abstract)98 
6  NR 14.6% - 
Lee et al, 201477 6  22 15.1% .076 
Lee et al, 201599 6  34 21.7% .029 
9  34 18.8% .026 
12 34 16.0% .023 
18 34 11.0% .016 
24 34 11.0% .016 
Lowry et al, 2016100 6  100 14.8% .035 
12 100 12.14% .032 
24 100 19.16% .040 
McIlraith et al, 200676 12 (Primary SLT) 74 31.0% .053 
12 (Sequential SLT) 87 25.6% .046 
Nagar et al, 200579 6  90ﻩ 35 18.3% .065 
180  ﻩ  49 25.9% .062 
360  ﻩ  44 40.4% .073 
12  90  ﻩ  35 21.6% .069 
180  ﻩ  49 32.6% .067 
360  ﻩ  44 43.7% .074 
Nagar et al, 200980 4-6 20 23.7% .067 
Rebenitsch et al, 
2013101 
12  NR 19.0% - 
Russo et al, 2009102 6  43 26.0% .066 
12  43 26.5% .067 
Schlote & 
Kynigopoulos, 2016103 
6  36 26.2% .032 
12  36 33.0% .036 
Tan et al, 2015 
(abstract)81 
6  78 14.5% .039 
Zaninetti & Ravinet, 
2008 (abstract) 
24  36 17.2% .062 
Zhang et al, 2015 
(abstract) 
6-9 (270  ﻩ ) 34 NR - 
6-9 (360  ﻩ ) 33 NR - 
NR: Not Reported; SLT: Selective laser trabeculoplasty; OAG: Open-angle Glaucoma; POAG: 
Primary Open-angle Glaucoma; PXG: Pseudoexfoliative Glaucoma; N: Number of eyes; SE: Standard 
Error; IOP: Intra-ocular pressure; IOPR: Intra-ocular pressure reduction 
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4.5.2 IOPR comparing SLT versus Medications 
Table 9 includes the IOP levels in both the SLT and the pharmacotherapy group. The 
percentage IOP reduction and the standard error was also calculated and reported in the 
table. For a follow-up time between 4-6 months, the IOP reduction averaged 24.3% 
(range: 15.1% to 40.4%) in the SLT group compared to 22.6% (range: 0 to 43.5%) in the 
pharmacotherapy group.  
At 9-12 months of follow-up the average percentage IOP reduction was 31.0% (range: 
21.6% to 43.7%) in the SLT group compared to 31.7% (range: 24.4% to 45.2%) in the 
pharmacotherapy group. There was one study that gathered data up until 60 months and 
the percentage IOP reduction for the SLT and medications-only group was 32.1% and 
33.2%, respectively.  
On average, the IOP percentage reduction was similar between the SLT group and the 
medications-only group. The study by Lee et al (2014)77 reported a zero percentage 
reduction at 6 months post initial medication treatment. Possible reasons include that the 
baseline IOP for the pharmacotherapy group was 14.5 (2.5), which was already low. 
What did change was the standard deviation (from 2.5 to 2.2), which means that the 
patients in the 6 months follow-up group had IOP values closer to the mean. Tan et al 
(2015)81 also reported a lower than average  percentage IOP reduction (3.16%) for the 
medications-only group. Reasons for this low percentage reduction could not be 
identified since the full text was written in Chinese.  
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Table 9:Follow-up of Included Studies Comparing SLT with Medications 
Author, 
Year of 
Publication 
Follow-
up 
(months) 
N of SLT 
Group 
Mean Post-
Operative 
IOP for SLT 
Group (SD) 
IOP 
Percentage 
Reduction 
for SLT 
Group 
SE_IOPR% 
(SLT Group) 
N of 
Medication 
Group 
Mean Post-
Operative 
IOP for 
Medication 
Group (SD) 
IOP 
Percentage 
Reduction 
for 
Medication 
Group 
SE_IOPR% 
(Medication 
Group) 
Katz et al 
201282 
4-6  38 18.9(2.9) 22.8% .068 31 17.8(3) 27.9% .081 
9-12 29 18.2(2.8) 25% .080 25 17.7(2.5) 26.7% .082 
Lee et al, 
201477 
6  22 13.4(2.3) 15.1% .076 19 14.5(2.2) 0 - 
Lai et al, 
200478 
6  24 18.8 (NR) 29.8% .093 24 19.1 (NR) 29.3% .092 
12  24 18.8(NR) 29.8% .093 24 19.8 (NR) 28.6% .092 
60  24 18.1(NR) 32.1% .095 24 17.5 (NR) 33.2% .097 
McIlraith et 
al, 200676 
[primary] 
12  74 17.8(3) 31% .053 26 16.9(NR) 30.6% .090 
McIlraith et 
al, 200676 
[wash-out] 
12  87 19.7(5) 25.6% .046 
Nagar, 
200579 
6  90  ﻩ  35 20(NR)* 18.3% .065 39 16.5(NR)* 43.5% .079 
180  ﻩ  49 22(NR)* 25.9% .062 
360  ﻩ  44 18(NR)* 40.4% .073 
12  90  ﻩ  35 19.2( NR)* 21.6% .069 39 16(NR)* 45.2%  .079 
180  ﻩ  49 20(NR)* 32.6% .067 
360  ﻩ  44 17(NR)* 43.7% .074 
Nager, 
200980 
4-6  20 16.4(NR) 23.7% .067 20 15(NR) 34.2% .075 
Tan et al, 
201581 
6  78 17.73(3.4) 14.5% .039 78 19.9(2.9) 3.16% .019 
Values with an Asterisk (*) mean that these values have not been provided by the article directly, and have been estimated from a graph 
IOP: Intra-ocular pressure; IOPR: Intra-ocular pressure reduction; SD: Standard Deviation; SE: Standard Error; NR: Not reported; N: Number of eyes; SLT: Selective 
laser trabeculoplasty 
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4.5.3 WMD in IOPR Comparing Sequential SLT with Medications 
A forest plot was created to examine whether the timing of the SLT procedure had an effect on 
IOP levels. The timing of the SLT procedure was divided into three separate groups. First, we 
looked at articles that compared Sequential SLT with pharmacotherapy. Sequential SLT was 
defined as SLT that was provided after a ‘wash-out’ period of about 4 weeks. During the “wash-
out” time, patients were not receiving any glaucoma medications or treatment.   
Figure 4 provides a forest plot depicting the WMD of the IOP percentage reduction in the 
Sequential SLT group and pharmacotherapy group. A significant IOP percentage reduction was 
seen in the pharmacotherapy group, WMD= 5.92% (95% CI [3.06, 8.79]) at 6 months follow-up 
and WMD= 2.73% (95% CI [0.24, 5.23]) at 12 months follow-up. Heterogeneity between studies 
that investigated the impact of Sequential SLT versus medications-only at 6 months (I2=99.9%) 
and at 12 months (I2=99.8%), was significantly high (p=0.00). Therefore, the random-effects 
model was computed. Furthermore, all four studies compared the Sequential SLT group with a 
prostaglandin analog only medication group.  
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Figure 4: Forest Plot for Studies Evaluating Sequential SLT versus Medications 
 
 
 
 
 
 
 
NOTE: Weights are from random effects analysis
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4.5.4 WMD in IOPR Comparing Adjunctive SLT with Medications 
A second forest plot was created to examine if the timing of the SLT procedure made a difference 
on the IOP-lowering effect. This forest plot assessed the IOP-lowering effect comparing 
Adjunctive SLT with pharmacotherapy. Adjunctive SLT was when a patient was already on 
topical glaucoma medications and SLT was performed. 
Figure 5 provides the forest plot of the IOP percentage reduction comparing Adjunctive SLT with 
pharmacotherapy at 6 months.Three77,78,81 studies reported data at 6 months follow-up. 
Significant percentage reduction in IOP in the Adjunctive SLT group, WMD= -8.98% (95% CI [-
17.19, -0.77]) compared to the pharmacotherapy group was seen. One78 study that had a follow-
up of 12 months and there was a 2.3% greater reduction in IOP in Adjunctive SLT group 
compared to pharmacotherapy group. Because there was only one study with a follow-up time of 
12 months, this was not included in the forest plot.  Heterogeneity (I2= 100%) between studies 
was significantly (p=0.00) high, therefore the random-effects model was computed. All three of 
the studies compared the Adjunctive SLT group to a mixed class of medications group. 
 
 
 
 
 
 
 
 
 
54 
  
 
Figure 5: Forest Plot for Studies Evaluating Adjunctive SLT versus Medications at 6 
months Follow-up 
 
 
 
 
 
 
 
 
 
NOTE: Weights are from random effects analysis
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4.5.5 IOPR comparing Primary SLT with Medications 
One76 study assessed the effect of Primary SLT versus pharmacotherapy on the IOP reduction. 
Primary SLT was defined as SLT being performed on patients with treatment naïve eyes, 
meaning the patient did not have any previous medications, lasers or surgical glaucoma 
treatment. The study76 found a 31% reduction in IOP in the Primary SLT group compared to a 
30.6% reduction in the latanoprost-only group. More studies need to be conducted comparing 
Primary SLT treatment with pharmacotherapy treatment in order to create a forest plot that 
illustrates the WMD in percentage IOP reduction between the two groups. Details on this study76 
can be found in Table 9.  
4.6 Impact on Medications 
4.6.1 Percent Reduction in Number of Medications after SLT 
Of the 31 studies, there were 27 studies that looked at post-operative reduction in medications as 
an outcome.  Eighteen77,81,83,87,88,90–96,99,100,102,103,105,106 studies gathered data at 6-9 months follow-
up however, only 1377,81,83,88,90,92,95,99,100,102,105,106 studies reported this data. An average 19% 
(range: -4% to 55%) reduction in medications was seen. There were 1978,83,85–90,92,93,95–97,99–103,106 
studies that gathered data at 12-18 months follow-up, but 1683,85,86,88–90,92,93,95,97,99–103,106,107 studies 
reported this data. An average 16.1% (range: -3.8% to 64%) reduction in medications was seen. 
Nine84,86,90,92,95,99,100,104,106 studies reported data on 24 months follow-up with mean reduction in 
medications averaging 13.8% (range: -3.8% to 40%). Five78,86,89,90,92 studies reported data on a 
follow-up of 36 months or greater with a 6.2% (range:-16.3 to 26.9%) mean reduction in 
medications. The medication reductions for each study at each follow-up is reported in Table 10. 
After assessing the articles, we found the three83,84,88 studies that reported the highest reduction in 
medications post SLT treatment included patients with the highest initial medications. Lai et al78 
reported a 16.3% increase in the medications at 60 months follow-up. This increase in 
medications could be due to worsening patients’ conditions, or the effect of SLT wearing off. 
Studies by Schlote & Kynigopoulos103, Rebenitsch et al.101 and Greninger et al.106 had reported 
the lowest percentage reduction in medications post SLT in chronic glaucoma patients over the 
age of 70.  
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Table 10: Medication Reduction from Baseline in Included Studies 
Author, Year of 
Publication 
Follow-up 
(months) 
N (eyes) Mean 
Medications 
(SD) 
Mean Reduction 
in Medications 
(SD) 
Mean 
Percentage 
Reduction in 
Medications 
Abdelrahman et 
al, 201283 
6 65 1(NR) 1.25(NR)  55% 
12 65 0.8 (NR) 1.45(NR) 64% 
18 65 1 (1.3) 1.25(1.1) 55% 
Babighian et al, 
201084 
24 15 0.87(0.8) 1.33(0.3) 39.5% 
Birt. 200785 12 30 2.2(1.6) 0.7(1.1) 24.1% 
Bovell et al, 
201186 
12 78 2.4(1.3) 0.2 (0.6) 7.7% 
24 79 2.1(1.2) 0.5 (0.5) 19.2% 
36 75 2.3(1.3) 0.3(0.8) 11.5% 
48 72 2.1(1.2) 0.5(0.6) 19.2% 
60 64 1.9(1.3) 0.7(0.8) 26.9% 
Bruen et al, 
201287 
6  56 NR  - - 
12 51 NR  - - 
Francis et al, 
200588 
6  66 0.7(0.9) 2.1(0.5) 25% 
12 60 1.5(0.9) 1.3(0.5) 46.4% 
Giocanti-Auregan 
et al, 201489 
(abstract) 
12 NR 1.36(0.8) 0.24(- ) 15% 
144 NR 1.3(1.2) 0.3( - ) 18.7% 
Greninger et al, 
2014106 
6  84 2.7(NR) -0.1 -3.8%(increase) 
12 80 2.7(NR) -0.1 -3.8%(increase) 
24 49 2.7(NR) -0.1 -3.8%(increase) 
Habib et al, 
201390 
8  79 2.10 (1.1) -0.07 -3.4%(increase) 
12 75 1.97 (1.1) 0.06 2.9% 
18 65 1.70(0.9) 0.33 16.2% 
24 45 1.83(1.1) 0.2 9.8% 
36 18 2.0(1.2) 0.03 1.5% 
Hirneib et al, 
201391 
6 (OAG) 68 NR - - 
6 (POAG) 45 NR - - 
Juzych et al, 
200492 
6  37 2.6(1.6) -0.1(0.2) -4%(increase) 
12 32 2.1(1.4) 0.4 (0.8) 16% 
24 29 2.3(1.4) 0.2 (0.8) 8% 
36 25 2.5(1.5) 0.2(1.1) 8% 
48 21 2.5(1.5) 0.2(1.2) 8% 
Kara et al,2013 93 6  48 NR - - 
12 48 2.4(1.3) 0.5(1.3) 26.3% 
Kent et al, 201594 6  NR NR 0.16(1.2) - 
Khouri et al, 
2014a95 
 
8  39 1.6(0.9) 0.1 (0.3) 5.1% 
12 38 1.6(0.9) 0.1 (0.3) 5.1% 
18 36 1.5(0.8) 0.2 (0.1) 11.7% 
24 28 1.5(0.8) 0.2 (0.4) 11.7% 
Khouri et al, 
2014b96 
8  42 NR - - 
12 43 1.45 (0.9) 0.12(0.4) 7.6% 
Koucheki & 
Hashemi. 201297 
16.6 78 2.1(0.7) 0.2(0.7) 8.7% 
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Table 10: Medication Reduction from Baseline in Included Studies (Continued) 
Author, Year of 
Publication 
Follow-up 
(months) 
N (eyes) Mean 
Medications 
(SD) 
Mean Reduction 
in Medications 
(SD) 
Mean 
Percentage 
Reduction in 
Medications 
Lai et al, 200478 12  24 0.46 (NR) 0 - 
60  24 0.55 (NR) -0.09 -16.3%(increase) 
Leon et al, 200598 6  NR NR NR - 
Lee et al, 201477 6  22 1.5(1.2) 0.8(0.5) 34.7% 
Lee et al, 201599 6  34 1.0(1.0) 0.5 33% 
12 34 1.0(0.8) 0.5 33% 
24 34 0.9(0.9) 0.6 40% 
Lowry et al, 
2016100 
6  81 2.45(0.3) .17(1.1 ) 6.48% 
12 81 2.56(0.9) 0.06(1.1) 2.3% 
24 81 2.76(0.3) -.14(1.1) -5.3%(increase) 
Rebenitsch et al, 
2013101 
12  NR 1.5(1.1) 0(-) 0 
Russo et al, 
2009102 
6  43 2.2(1.2) 0.1 (0.5) 4.3% 
12 43 2.2(1.1) 0.1 (0.5) 4.3% 
Schlote & 
Kynigopoulos, 
2016103 
6  36 1.9(1.0) 0 0 
12 36 1.9(1.0) 0 0 
Tan et al, 201581 6  78 2.19(0.3) 1.04(0.3) 47.5% 
Zaninetti & 
Ravinet, 2008104 
24  36 1.36(NR) 
drops/patient 
.08( - ) 5.5% 
Zhang et al, 
2015105 
6-9 (270°) 34 1.3(0.5) 1(0.5) 43.5% 
6-9 (360°) 33 1.1(0.3) 1(0.3) 47.6% 
NR: Not reported; OAG: Open-angle Glaucoma; POAG: Primary Open-angle Glaucoma; N: Number of eyes; SD: Standard 
Deviation 
*Lai et al, 2004: the baseline number of medications was not provided. The number of medications at 12 months was used as 
the baseline to calculate the percentage reduction at 60 month 
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4.6.2 WMD of Pre-and-Post SLT Medications 
Figure 6 is a forest plot that illustrates the pre-and-post-operative topical glaucoma medications. 
The data are divided into seven different follow-ups: 6 to 11 months, 12 to 17 months, 18 
months, 24 months, 36 months, 48 months, and 60 months. 
Thirteen77,81,83,88,90,92,93,95,99,100,102,103,105 studies reported 6 to 11 months follow-up, 
1483,85,86,88,90,92,93,95–97,99,100,102,103 studies reported 12 to 17 months follow-up, three83,90,95 studies 
reported 18 months follow-up, five86,90,92,99,100 studies reported 24 months follow-up, three86,90,92 
studies reported 36 months follow-up, two86,92 studies reported 48 and 60 months follow-up. 
Studies that did not report on a sample size were not included in the forest plot but were included 
in the tables. 
Heterogeneity between studies that reported reduction in medications at 6 to 11 months follow-up 
(I2=95%, p=0.00), at 12 to 17 months follow-up (I2=86.3%, p=0.00), 18 months follow-up (I2= 
88.1%, p=0.00), 24 months follow-up (I2= 68.5%, p=0.013) was significantly high. At 36 months 
follow-up (I2= 0%, p=0.70), 48 months follow-up (I2= 8.1%, p=0.29), and 60 months follow-up 
(I2= 46.5%, p=0.17) there was non-significant between study heterogeneity.  
There was a significant reduction in post-operative medications at 6 to 11 months follow-up, 
WMD= -0.55 medications (95% CI [-0.90, -0.20]), at 12 to 17 months follow-up there was also a 
significant reduction, WMD= -0.32 medications (95% CI [-0.62, -0.02]). There was a non-
significant reduction at 18 months follow-up WMD= -0.59 medications (95% CI [-1.21, 0.03]),  
at 24 months follow-up WMD= -0.26 medications (95% CI [-0.58, 0.06]), at 36 months follow-
up  WMD= -0.19 medications (95% CI [-0.52, 0.13]), at 48 months follow-up WMD= -0.40 
medications (95% CI [-0.79, 0.00]), and at 60 months follow-up WMD= -0.47 medications (95% 
CI [-1.11, 0.18]). 
Overall, there was a slight lean towards favoring SLT at all follow-up times, and there was a 
significant reduction in the number of pre-and-post-operative medications at 6 to 11 months and 
12 to 17 months of follow-up, however these results should be interpreted with caution as there 
was high heterogeneity reported in these subgroups. 
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Figure 6: Forest Plot of Medications Pre-and-Post SLT 
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4.6.3 Subgroup Analysis by SLT Degree 
A subgroup analysis was conducted to determine if the SLT degree, specifically whether SLT 
was applied over 360 degrees or 180 degrees of TM, made any impact on the reduction in 
medications. Figure 7 depicts a forest plot of medications pre-and-post SLT at 6 to 11 months 
follow-up. There were nine77,81,83,90,95,99,100,102,105 studies that reported data on SLT preformed 
over 360 degrees of the TM and there was a significant reduction in medications, WMD= -0.58 
medications (95% CI [-0.89, -0.29]), with a significant between study heterogeneity (I2= 92.7%, 
p=0.00). There were three88,92,103 studies that performed SLT treatment over 180 degrees of the 
TM. There was a non-significant reduction in medications, WMD=-0.79 medications (95% CI [-
2.29, 0.71]), with significant between study heterogeneity (I2=96.8%, p=0.00).  
Figure 8 depicts a forest plot reporting the WMD of the medications reduction before and after 
SLT for studies that reported follow-up times from 12 to 17 months. Eight83,90,95–97,99,100,102 
studies reported data for 360 degrees of SLT treatment, and there was a non-significant reduction 
in medications pre-and-post SLT, WMD= -0.34 medications (95% CI [-0.77, 0.10]), with 
significant between study heterogeneity (I2= 90.5%, p=0.00).  Six85,86,88,92,93,103 studies reported 
data for SLT preformed over 180 degrees of the TM. There was a non-significant reduction in 
medications post SLT, WMD= -0.29 medications (95%CI [-0.67, 0.09]), with significant between 
study heterogeneity (I2=74.2%, p=0.00).   
Overall, based on the forest plots, there appeared to be a significant reduction in medications at 6 
months post SLT when a patient received 360 degrees of treatment over the TM. However, by 12 
months follow-up, the significant effect may ware off. Providing SLT at 180 degrees did not 
appear to significantly reduce the medications at 6 months or 12 months post SLT treatment. Due 
to high heterogeneity, the random effects model was used. 
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Figure 7: Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 6-11 Months 
Follow-up 
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Figure 8: Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 12-17 Months 
Follow-up 
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4.6.4 Subgroup Analysis by Study Design 
A subgroup analysis was conducted by study design. Figure 9 reports data for 6 to 11 months 
follow-up post SLT treatment. Eight83,88,90,92,95,99,100,103 studies reported data from non-RCT 
studies. The non-RCT studies showed a non-significant reduction in medications, WMD= -0.54 
medications (95% CI [-1.16, 0.07]), and a significant between study heterogeneity (I2= 96%, 
p=0.00). Four77,81,102,105 RCTs showed a significant reduction in medications, WMD= -0.89 
medications (95% CI [-1.14, -0.63]). Heterogeneity (I2= 77.6%, p=0.00) between RCTs was 
significantly high.  
Figure 10 reports data for 12 to 17 months follow-up post SLT treatment. Twelve83,85,88,90,92,93,95–
97,99,100,103studies reported data from non-RCT studies. There was a significant reduction in 
medications, WMD= -0.35 medications (95% CI [-0.68, -0.01]). Heterogeneity (I2=88%, p=0.00) 
between studies was significant. There were two86,102 studies that reported data from RCTs, and 
there was a non-significant reduction in medications, WMD= -0.16 medications (95% CI [-0.47, 
0.15]). Non-significant heterogeneity (I2=0%, p=0.76) existed between these two studies.  
Based on Figures 9 and 10, RCT study results suggest a significant reduction in medications at 6 
to 11 months follow-up. However, a non-significant reduction was observed at 12 to 17 months. 
This conclusion is based off of two RCTs and thus more RCTs are required to make concrete 
conclusions. With the non-RCT studies, a non- significant reduction in medications was observed 
at 6 to 11 months follow-up, and there was a significant reduction at 12 to 17 months follow-up. 
These results should not be viewed as definitive because of high heterogeneity.  However, it is 
important to note that the heterogeneity was lower in the RCT studies, which suggested that the 
non-RCT studies may have a higher heterogeneity due to high confounding within the studies, 
which the RCT studies have controlled for through randomization of participants. 
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Figure 9: Forest Plot of Medications Pre-and-Post SLT by Study Design at 6-11 Months 
Follow-up 
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Figure 10: Forest Plot of Medications Pre-and-Post SLT by Study Design at 12-17 Months 
Follow-up 
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4.7 Impact on Adverse Events 
Of the 31 included studies, 2176–79,82–86,88,89,91–94,97,100–103,106 reported on adverse events that 
occurred after SLT treatment. Eleven78,79,83,84,86,88,93,97,100,102,106 studies reported an IOP spike, 
ten78,79,83,86,88,93,97,100,102,106 studies reported on the number of IOP spikes observed. There were at 
least 72 cases of IOP spikes among 1,742 eyes that underwent SLT, which was approximately 
4.13%. All of the studies had a different definition for IOP spike. Four78,79,83,88 studies defined a 
spike as an IOP greater than 5mm Hg within 24 hours of operation. Four86,97,102,106 studies defined 
an IOP spike as an IOP of greater than or equal to 6mm Hg within 24 hours of operation. Lowry 
et al100 defined IOP spike as an IOP greater than 7 mm Hg and Babighian et al84 stated that the 
IOP spikes did not exceed 8 mm Hg. Three79,83,93 studies reported that patients experienced ocular 
discomfort. The types of ocular discomfort were not described in the articles. A flare or 
inflammation of the anterior chamber was reported in two76,84 studies. Five85,86,97,100,103 studies 
reported that the patient required additional intervention to stabilize the IOP levels. A detailed list 
of all reported complications is provided in Table 11.  
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Table 11: Reported Adverse Events Post SLT Treatment 
Author, Year of Publication Reported Complications Post SLT 
Abdelrahman et al, 201283 Ocular discomfort, IOP rise 1 week following SLT (5 cases), IOP 
spike associated with a mild flare in the anterior chamber 
Babighian et al, 201084 Flare of anterior chamber (2 cases), IOP spike (2 cases) 
Birt. 200785 Trabeculectomy (5), Further laser therapy (7) 
Bovell et al, 201186 IOP spike (3 cases), Additional interventions including Ahmed Valve 
(5 cases), Repeat SLT (17 cases), ALT (5 cases), Trabeculectomy 
Mitomycin C (14 cases), Diode cyclophotocoagulation (1 case), 
Cateract extraction with intraocular lens implant/Trabeculectomy with 
Mitomycin C (10 cases) 
Bruen et al,201287 - 
Francis et al, 200588 IOP spike (6 cases) 
Giocanti-Auregan et al,201489 No significant complications 
Greninger et al, 2014106 IOP spike (8 cases),  cystic macular edema (1 case), Corneal epithelial 
defect (1 case) 
Habib et al, 201390 - 
Hirneib et al, 2013 91 No adverse events after SLT 
Juzych et al, 200492 Complications treated but not reported 
Kara et al, 201393 IOP spike (7 cases), Iritis (5 cases), Ocular discomfort (16 cases) 
Katz et al, 201282 No IOP elevation or uveitis, no peripheral anterior synechiae 
Kent et al, 201594 Specifically no IOP spikes reported. Defined as an IOP increase of 6 or 
more mm Hg after 1 hour of SLT 
Khouri et al, 2014a95 - 
Khouri et al, 2014b96 - 
Koucheki & Hashemi, 201297 Mild pain during SLT (23.5%), Inflammation in eyes (42.6%), IOP 
spike (6 cases), Further surgical intervention (17.6%) 
Lai et al, 200478 IOP spike (3 cases), No persistent anterior chamber reaction beyond 1 
week 
Leon et al, 200598 - 
Lee et al, 201477 No complications from the laser procedure 
Lee et al, 201599 - 
Lowry et al, 2016100 IOP spikes (6 cases), Further surgery (9%) 
McIlraith et al, 200676 Minimal inflammatory reaction (33 cases), Flare (+1) (3 cases) 
Nagar et al, 200579 IOP spike (24 cases), Ocular discomfort (29 cases), mild uveitis (53 
cases) 
Nagar et al, 200980 - 
Rebenitsch et al, 2013101 No adverse effects reported 
Russo et al, 2009102 Anterior chamber inflammation (12 eyes), IOP spike (6 cases) 
Schlote & Kynigopoulos, 2016103 1 abnormal wound healing, trabeculecomy because of insufficient IOP 
reduction (8 eyes), filtration surgery 
Tan et al, 201581 - 
Zaninetti & Ravinet, 2008104 - 
Zhang et al, 2015105 - 
IOP: Intra-ocular pressure; mm Hg: millimeters of mercury; SLT: Selective laser trabeculoplasty; ALT: 
Argon laser trabeculoplasty 
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4.7 Sensitivity Analysis 
The sensitivity analysis was conducted to examine the robustness of the results. In Figure 4, 
we found that Sequential SLT versus pharmacotherapy at 6 months and 12 months follow-up 
had an IOP-lowering effect that favored pharmacotherapy. We re-ran this forest plot, 
excluding a study by McIlraith et al.76, and found that the results remained the same (See 
Figure 11).Significant reduction in IOP was seen at 6 months in the pharmacotherapy group 
compared to the Sequential SLT group, WMD= 6.23% (95% CI [1.90, 10.57]). 
Heterogeneity between studies was found to be significant (I2=99.9%, p=0.00).At 12 months 
a significant reduction in IOP occurred in the pharmacotherapy group compared to the 
Sequential SLT, WMD= 1.60% (95% CI [1.40, 1.79]). Moderate heterogeneity (I2=42.8%, 
p=0.18) was observed.  
Figure 5 illustrated a forest plot of the WMD comparing Adjunctive SLT with 
pharmacotherapy. At 6 months follow-up there were two full-text articles and one abstract 
only, and the IOP-lowering effect favored the SLT group, WMD=-8.98% (95% CI [-17.19, -
0.77]). When we re-ran the forest plot, and excluded the abstract81, we found similar results. 
(See Figure 12).The WMD of Adjunctive SLT and medications-only group showed no 
significant difference, WMD=-7.50% (95% CI [-22.20, 7.20]). Heterogeneity (I2= 100%, 
p=0.00) was significant between studies.  
Figure 6 illustrated a forest plot of the WMD of the medication reduction pre-and-post SLT. 
At all follow-up times, except for 6 to 11 months and 12 to 17 months post SLT treatment, 
there was a non- significant reduction in medications after SLT treatment.  We re-ran the 
forest plot eliminating the abstracts: Tan et al81 and Zhang et al105. This strategy produced 
different results. (See Figure 13). There were 1177,83,88,90,92,93,95,99,100,102,103 studies included at 
6 to11 months follow-up, 1483,85,86,88,90,92,93,95–97,99,100,102,103 studies included at 12 to 17 
months follow-up, three83,90,95 studies included at 18 months follow-up, five86,90,92,99,100 
studies included at 24 months follow-up, three86,90,92 studies included at 36 months follow-
up, two86,92 studies included at 48 and 60 months follow-up. 
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There was a non-significant reduction in medications at 6 to 11 months follow-up, WMD= -
0.43 medications (95% CI [-0.95, 0.08]) post SLT. Significant heterogeneity (I2=95.2%, 
p=0.00) was seen. At 12 to 17 months follow-up the WMD remained significant, WMD= -
0.32 medications (95% CI [-0.62, -0.02]), with significant between study heterogeneity 
(I2=86.3%, p=0.00). There was a non-significant reduction in medications at 18 months 
follow-up, WMD= -0.59 medications (95% CI [-1.21, 0.03]) with significant between study 
heterogeneity (I2= 88.1%, p=0.00), at 24 months follow-up, WMD=-0.26 medications (95% 
CI [-0.58, 0.06]), with significant heterogeneity (I2= 68.5%, p=0.01). At 36 months follow-
up a non-significant reduction in medications was seen, WMD= -0.19 medications (95% CI 
[-0.52, 0.13]), with a non-significant heterogeneity (I2= 0%, p=0.70).A non-significant 
reduction in medications was seen at 48 months, WMD= -0.40 medications (95% CI [-0.79, 
0.00]), with a non-significant heterogeneity (I2= 8.1%, p=0.29), and WMD= -0.47 
medications (95% CI [-1.11, 0.18]) at 60 months with a moderate between study 
heterogeneity (I2= 46.5%, p=0.17).  
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Figure 11: Sensitivity Analysis for Studies Evaluating Sequential SLT versus Medications 
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Figure 12: Sensitivity Analysis for Studies Evaluating Adjunctive SLT versus Medications 
 
 
 
 
 
 
 
 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 100.0%, p = 0.000)
Lai
Author
Lee
Year of
2004
Publication
2014
SLT
360
Degree
360
Sample
48
Size
41
-7.80 (-22.11, 6.51)
-0.50 (-0.78, -0.22)
WMD (95% CI)
-15.10 (-15.27, -14.93)
100.00
%
50.00
Weight
50.00
Favors SLT  Favors Medications 
0-22.1 22.1
72 
  
 
Figure 13: Sensitivity Analysis for Studies Evaluating the Pre-and-Post SLT Number of 
Medications 
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4.8 Summary of Findings 
Table 12 provides a summary of the main findings reported in the results. 
Table 12: Summary of Main Findings 
Research 
Questions  
Results Interpretation 
What is the IOP-
lowering effect 
between Sequential 
SLT and 
medications-only? 
6 months post SLT treatment:  
WMD= 5.92% (95% CI [3.06, 8.79]) 
 
12 months post SLT treatment: 
 
WMD= 2.73% (95% CI [0.24, 5.23]) 
Significant difference favoring 
the medications-only group 
What is the IOP-
lowering effect 
between 
Adjunctive SLT 
and medications-
only? 
 
6 months post SLT treatment: 
 
WMD= -8.98% (95% CI [-17.19, -0.77]) 
Significant difference favoring 
the Adjunctive SLT group 
Does SLT 
significantly reduce 
the number post-
operative 
medications? 
 
 
 
6 months post SLT treatment: 
 
WMD= -0.55 medications (95% CI [-0.90, -0.20]) 
 
12 months post SLT treatment: 
 
WMD= -0.32 medications (95% CI [-0.62, -0.02]) 
 
Significant reduction in 
medications at 6 and 12 months 
follow-up. All other follow-ups 
showed no significant reduction 
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Chapter 5  
5 Discussion 
5.1 Summary of Quantitative Results 
The aim of this thesis was to assess the effectiveness of SLT as an intervention in adult patients 
who were diagnosed with OAG or OHT. The first research question addressed whether SLT was 
effective at reducing patient’s IOP levels compared to traditional pharmacotherapy. This was 
based on the assessment of 689 eyes. Providing SLT adjunctively was more effective at reducing 
the IOP levels than medications-only. Further, when the SLT group was ‘washed-out’ of the 
medications, the IOP-lowering effect favored the medications-only group both at 6 months and 
12 months follow-up. There was only one study that compared Primary SLT with 
pharmacotherapy and the results showed that when SLT was provided as primary treatment, the 
IOP reduction favored the SLT group.  
The second research question addressed whether SLT would significantly reduce the post-
operative medications. We gathered data on 1,742 eyes who underwent Adjunctive SLT 
treatment. We assessed the WMD in the number of medications from baseline to 6-11, 12-17, 18, 
24, 36, 46, and 60 months of follow-up. At all follow-up points, the medication reduction 
favored SLT treatment; there was a significant reduction in medications post-SLT at 6 to 11 
months and 12 to 17 months. However, based on the sensitivity analysis and the high 
heterogeneity between the studies, concrete conclusions cannot be made. 
When we conducted a subgroup analysis based on the SLT degree, we found that providing SLT 
over 360 degrees of the TM significantly reduced topical glaucoma medications at 6 to 11 
months follow-up, but not at 12 to17 months follow-up. Providing SLT over 180 degrees of the 
TM showed no significant reduction in medications at 6 to 11 months and at 12 to 17 months 
follow-up. When we conducted a subgroup analysis based on the study design, we found that the 
RCTs showed a significant reduction in medications post-operatively, at 6 to 11 months follow-
up. At 12 to 17 months follow-up the non-RCTs showed a significant reduction in medications. 
There was high heterogeneity reported in the subgroup analyses and these results should not be 
viewed as conclusive.  
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5.2 Interpretation of Results 
The majority of clinicians use a 20% IOP reduction from baseline as the determining factor for 
the success of SLT treatment39. The average IOP percentage reduction was 21.3% at 6-9 months 
follow-up, 22.4% at 12 months follow-up, and approximately 17% at 18-24 months follow-up. In 
general, SLT provided as an adjunctive treatment, met the definition of a ‘successful’ treatment 
option up until approximately 24 months, which corroborates with conclusions made in the 
literature22. 
A possible reason some studies reported a higher percentage IOP reduction is that their baseline 
IOPs were higher. As expected, the cumulative IOP-lowering effect of multiple interventions 
produced a greater IOP reduction. The Adjunctive SLT group, which consisted of patients who 
were taking medications concurrently with SLT treatment, had a greater IOP reduction compared 
to the pharmacotherapy group. Furthermore, this study has revealed that the order in which SLT 
was provided to patients in their treatment regimen may play a role in SLT’s success.  
When SLT was provided after a wash-out of medications, SLT did not have a stronger effect on 
lowering IOP levels compared to medications-only group. A study conducted by Ault and 
Hutnik, (2016)108 assessed a group of patients who were initially on medications. The patients 
were randomized to two groups. One group of patients who were washed-out of prostaglandin 
analog medications for 6 weeks, and then provided SLT, and another group who continued on 
prostaglandin analog treatment. The baseline IOP was approximately 26.6 (SD: 1.6) mm Hg 
before the commencement of the study. When all patients took prostaglandin analogs, their IOP 
reduced to 14.5(SD: 0.6) mm Hg. The patients who were washed-out of prostaglandin analogs 
for 6 weeks, their IOP rose only to 20.3(SD: 2.6) mm Hg, which was significantly lower than the 
initial baseline IOP. Results from this study indicated that the impact of the prostaglandin 
analogs may still be lingering in the eye well after the discontinuation of the medications; this 
may be a reason why the Sequential SLT group had a smaller IOP-lowering effect. However, 
more research needs to be conducted to determine the underlying reasons for this observation.  
It is important to note that sometimes the intention of SLT as an additional intervention may not 
be to reduce IOP by a significant amount; sometimes the intention may be to help reduce the 
patient’s dependency on medications. In our analysis, on average, the studies that reported the 
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greatest number of baseline medications, also reported the greatest percentage reduction in 
medications, suggesting that SLT was effective at lowering medications when a patient was 
taking 3 to 4 medications compared to 1 or 2 medications. Furthermore, based on the results of 
this study, we could not definitively conclude which types of glaucoma medications worked best 
with SLT because there were only 877,84–88,97,99 studies that reported on the type of medications 
that were prescribed to the patients and the majority of the 8 studies did not provide detailed 
information on how the medications were taken. 
In regard to the exploratory investigation analyzing the adverse events as a result of SLT, we 
found that out of the 31 studies, 21 studies mentioned adverse events post SLT. The most 
commonly reported adverse events included post-operative IOP spike within 24 hours, and 
ocular discomfort. These complications, as well as other complications reported, were treated 
using steroids or non-steroidal anti-inflammatory eye drops39. There are some cases where SLT 
cannot be performed on a patient. SLT cannot be performed when a patient has closed or very 
narrow angles, severe kyphosis, ankylosing spondylosis, torticollis or cervical arthritis, head 
tremors, or eyes that are deeply recessed109. With the exception of these cases where SLT cannot 
be performed, SLT could be considered for OAG or OHT patients. Our results supported 
previously published conclusions which have stated that there were no extreme complications 
associated with SLT, suggesting that SLT was a safe procedure.  
5.3  Strengths and Limitations 
A major strength of this study was the research design. Systematic reviews and meta-analyses 
help clinicians keep track of current data in a particular subject area by summarizing all 
previously published results into one paper. This allows clinicians to make evidence-based 
decisions on the best possible treatment options without having to sift through multiple research 
studies. Systematic reviews provide a non-biased comprehensive review of the literature that 
involves creating a search strategy to gather as many relevant articles as possible. The process of 
systematically reviewing articles reduces the chance of study selection bias72. Further, in total, 
the results were based on 2,431 eyes and  follow-up times ranged from 4-6 months to 60 months. 
A limitation of this study was the high heterogeneity. The heterogeneity reported in the forest 
plots ranged from 0% to 100%. High heterogeneity meant that variations in study results were 
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due to something other than chance. Possible reasons could be that there was no standard way for 
SLT to be performed on patients. From study to study, SLT differed on the degree, the clock 
hour the treatment was provided, the number of laser spots applied, whether or not the spots were 
applied contiguously, the type of medications provided, and the anti-steroidal and anti-
inflammatory drugs provided directly before and after SLT treatment. Furthermore, the patients 
were from differing age groups and differing stages of the disease. 
A second limitation was scarce evidence. Four studies evaluated SLT sequentially, three studies 
evaluated SLT adjunctively and only one study evaluated SLT as primary treatment. Even 
though patients who underwent Sequential SLT were washed-out of the medications, the 
lingering effect of the medications persisted, and we wanted to assess whether SLT, by itself, 
without any previous medications, would result in a greater IOP-lowering effect when compared 
to medications alone. The small number of relevant studies made this comparison difficult.  
A third limitation was the inclusion of studies irrespective of their quality. Data were included 
from non-randomized clinical trials, various observational studies, and abstracts. Ideally all 
included studies would be RCTs however, due to the limited amount of studies, we could not 
eliminate studies based on quality.  
A fourth limitation was that we assumed that the pre-and post-operative  IOP were independent. 
Based on this assumption, as well as literature2, computations were conducted. Further, based on 
the literature, we computed the SE_IOPR%. Given this limitation in computing the SE_IOPR%, a 
potential to address this limitation in the future does exist.  
5.4 Implications of Practice and Future Research 
For future practice, these results suggested that providing SLT concurrently with a combination 
of drugs may have the potential to reduce the medications in order to diminish non-compliance 
issues. In a best case scenario, the medical treatment adherence is 75%, and when patients are 
prescribed two or more medications, the adherence drops39.  Patients who are non-compliant to 
their treatment regimen will incur higher medical costs because their disease status will 
worsen47.A study conducted by Cate et al110 found that providing an educational and 
motivational support package using behavioral change counseling made no difference in 
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medication adherence. Clements (2012)109 reported that telephone reminders and tailored 
printing material also did not help with medication adherence. 
Since the majority of the patients that underwent SLT had undergone previous medical 
treatment, we could not definitively conclude how much of an independent role SLT played in 
lowering the IOP. For this reason, more studies are required comparing SLT in patients with 
treatment naïve eyes to SLT in patients on medications. A study conducted by Onakoya et al.111 
compared SLT as primary therapy in treatment naïve eyes to patients who had SLT and 
medications concurrently (Adjunctive SLT). There were 89 eyes with POAG included in the 
analysis. They found a similar IOP reduction in both groups. This may suggest that just as the 
Adjunctive SLT group was more effective at lowering the IOP levels than the pharmacotherapy 
group in our study, the Primary SLT group may have a greater reduction in IOP compared to the 
pharmacotherapy group. This could further imply that a patient would not need to take any 
additional medical treatment, which could save a patient hundreds of dollars per year in medical 
costs. This was only an inference and a more concrete conclusion could be made if there were 
more studies comparing Primary SLT treatment with medications-only treatment. 
There are currently no standardized procedures for how SLT should be administered to patients. 
More studies should be conducted comparing different ways of administering SLT. Once an 
ideal SLT administration is found, this method could be standardized globally. This will make 
future studies that are included in meta-analysis, which aims to assess the effectiveness of SLT, 
more comparable and homogenous.   
Additionally, future clinical trials should provide a clear description of the types of medications 
prescribed. In the studies that assessed the pre-and-post-operative medications, most studies did 
not specify which types of medications were used. This information could have been imperative, 
because we may have been able to determine whether SLT worked better with certain types of 
drugs. Also, there need to be more studies to assess steroid or anti-inflammation drug use in the 
effectiveness of SLT.  
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5.5 Conclusion 
This systematic review and meta-analysis concluded that SLT is an effective and safe treatment 
option for patients with OAG or OHT. In addition, this study illustrated that SLT’s effectiveness 
depended on when it was provided in the treatment paradigm. Out of all of the treatment 
strategies that were analyzed, Adjunctive SLT was found to be more effective than 
pharmacotherapy at lowering IOP levels, as well as lowering medications. Finally, since the 
majority of medical drug coverage plans only pay for a portion of fees and the patient is left to 
pay the difference, SLT may be the more cost effective approach since the treatment is covered 
by OHIP.  
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Appendices 
Appendix 1: PRISMA Checklist 
Section/topic  #  Checklist item  
Reported on 
page #  
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both i 
ABSTRACT 
Structured 
Summary 
2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.   
ii 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known 15-17 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).   
17 
METHODS 
Protocol and 
registration   
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.   
18 
Eligibility criteria   6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.   
19 
Information 
sources   
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.   
18 
Search   8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.   
Appendix 2 
Study selection   9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).   
19-20 
Data collection 
process   
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.   
22 
Data items   11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.   
21-23 
Risk of bias in 
individual studies   
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.   
22-23 
Summary 
measures   
13 State the principal summary measures (e.g., risk ratio, difference in means).   23-24 
Synthesis of 
results   
14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2)for each meta-analysis.   
24-26 
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Appendix 1: PRISMA Checklist (Continued) 
 
Section/topic  #  Checklist item  
Reported on 
page #  
Risk of bias 
across studies   
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).   
27-28 
Additional 
analyses   
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.   
27 
RESULTS 
Study selection   17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.   
38-39 
Study 
characteristics   
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.   
29-37 
Risk of bias 
within studies   
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).   
40-41 
Results of 
individual studies   
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.   
46-51, 56-58, 
66-67 
Synthesis of 
results   
21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.   
51-54 
Risk of bias 
across studies   
22 Present results of any assessment of risk of bias across studies (see Item 15).   43-45 
Additional 
analysis   
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).   
68-72 
DISCUSSION 
Summary of 
evidence   
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).   
74 
Limitations   25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).   
76-77 
Conclusions   26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.   
75-76, 77-79 
FUNDING 
Funding   27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.   
103 
 
 
  93 
 
Appendix 2: Search Strategy 
MEDLINE(Ovid)  Search Terms 
1 1. Mesh    
 
ocular hypertension/ or 
glaucoma/ or intraocular 
pressure/ 
 
2 2. Keyword Search  
 
(glaucoma* or ocular 
hypertension or intraocular 
pressure or intra-ocular 
pressure).mp. 
 
3 1 or 2 Total Including Limits 
75069  
 
 
4 1. Mesh  TM/ or trabeculecomy/ or 
glaucoma/ 
5 2. Keyword Search    
 
(trabeculoplast* or goniotom* or 
trabeculotom* or slt or selective 
laser trabeculoplast*).mp 
 
6 4 or 5 Total Including Limits 
36552  
 
 
7 1. Mesh   
 
prostaglandins/ or prostaglandin/ 
or synthetic prostaglandin 
analogs/ 
 
8 2. Keyword Search  (Prostaglandin analogs or 
Prostaglandin* or latanoprost or 
bimatoprost or travoprost).mp. 
9 7 or 8 Total Including Limits 116289 
10 1. Mesh adrenergic beta-agonists/ or 
levobunolol/ or timolol/ or 
adrenergic beta-1 receptor agonists/ 
or betaxolol/ 
11 2. Keyword Search  
 
(Beta blocker* or B-blocker* or 
Timolol or Betaxolol or 
levobutonol).mp. 
 
12 10 or 11 Total Including Limits 
55062  
 
 
13 1. Mesh  Carbonic Anhydrase Inhibitors/ or 
CAI/ 
14 2. Keyword Search (Carbonic anhydrase inhibitor* or 
Carbonate dehydratase inhibitor* or 
dorzolamide or brinzolamide).mp. 
15 13 or 14 Total Including Limits 5113 
16 1. Mesh Receptors/ or Adrenergic/ or alpha/ 
or exp Hypertension/ or Adrenergic 
alpha-Agonists/ 
17 2. Keyword Search 
 (Alpha-agonist* or brimonidine 
or Alphagan).mp. 
 
18 16 or 17 Including Limits 
239,978  
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19 3 AND 6 AND (9 OR 12 OR 15 OR 
18) 
 
 
562 Articles 
The following Limits were applied:  
-19 plus years of age 
-Article published after 1997 
-Human Subjects 
-English Articles  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  95 
 
EMBASE (Ovid)  Search Terms 
1 1. Emtree glaucoma/ or intraocular pressure/ 
or ocular hypertension/ 
2 2. Keyword Search (glaucoma* or ocular hypertension 
or intraocular pressure or intra-
ocular pressure).mp. 
 
3 1 or 2 107,631 
4 Emtree  Trabeculoplasty/ or laser therapy/ 
or selective laser trabeculectomy/ or 
SLT/ 
5 1. Keyword Search 
 
(Trabeculoplast* or gonotom* or 
trabeculectom* or slt or selective 
laser trabeculoplast*).mp. 
 
6 4 or 5 
21591  
 
 
7 Emtree  prostaglandin/ or prostaglandin 
analog/ 
 
8 1. Keyword Search  (Prostaglandin analogs or 
prostaglandin* or latanoprost or 
bimatoprost or travoprost).mp. 
9 7 or 8 
173879  
 
 
10 1. Emtree exp beta adrenergic receptor 
blocking agent/ or exp atenolol/ or 
exp hypertension/ 
11 2. Keyword Search (Beta blocker or b-blockers or 
timolol or betaxolol or 
levobutonol).mp. 
12 10 or 11 
805233  
 
 
13 1. Emtree Carbonate Anhydrase inhibitor/ or 
CAI/ or CAIS/ 
14 2. Keyword Search 
 
(carbonic anhydrase inhibitor* or 
carbonate dehydratase inhibitor* 
or dorxolamide or 
brinzolamide).mp 
 
15 13 or 14 
6195  
 
 
16 1. Emtree Alpha agonist/ or adrenergic alpha-
agonist/ or alpha-adrenergic 
agonist/ 
17 2. Keyword 
 (Alpha-agonist* or brimonidine 
or Alphagan).mp. 
 
18 16 OR 17 
12518  
 
 
19 (3 AND 6) AND ( 9 OR 12 OR 15 
OR 18) 
limit 21 to (human and english 
language and yr="1997 -Current" 
and (adult <18 to 64 years> or aged 
<65+ years>)) 
550 Articles were extracted from 
Embase. 
The following restrictions were 
applied: 
-English articles 
-1997-  
-Human Adults 18+ 
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CINAHL  Search Terms  
1 1. (MM "Intraocular Pressure") OR 
(MM "Ocular Hypertension") OR 
(MM "Glaucoma")  
2 2. (Glaucoma* OR 
Ocular hypertension OR intraocular 
pressure OR intra-ocular pressure) 
3 1 or 2  
4 1. (MH "Laser Therapy") 
5 2. (Trabeculoplast* OR 
Goniotom* OR 
Trabeculotom* OR 
SLT ) 
6 4 or 5  
7 1. (MH "Prostaglandins, Synthetic+") 
OR (MH "Prostaglandins I") OR 
(MH "Prostaglandins E") OR (MH 
"Prostaglandins") 
8 2. Prostaglandin analogs OR 
Prostaglandin* OR latanoprost OR 
bimatoprost OR travoprost 
9 7 or 8  
10 1. (MH "Adrenergic Beta-Agonists") 
OR (MH "Timolol") OR (MH 
"Levobunolol Hydrocholoride") OR 
(MH "Betaxolol Hydrochloride")  
11 2. (Beta blocker OR B-blocker OR 
Timolol  OR Betaxolol OR 
Levobutonol) 
12 10 or 11  
13 1. (MH "Acetazolamide") OR (MH 
"Brinzolamide") OR (MH 
"Methazolamide") OR (MH 
"Dichlorphenamide") OR (MH 
"Dorzolamide Hydrochloride")  
14 2. (Carbonic anhydrase inhibitor* OR 
Carbonate dehydratase 
inhibitor*OR dorzolamide OR 
brinzolamide) 
15 13 or 14  
16 1. (MH "Brimonidine Tartrate-
Timolol Maleate") OR (MH 
"Adrenergic Alpha-Agonists")  
17 2. Alpha-agonist* OR brimonidine 
OR Alphagan 
18 16 or 17 
 
19 [3 AND 6] AND [ 9 OR 12 OR 15 
OR 18] 
13 articles were included from this 
database with the following limits  
-English only 
-published 1997- 
-adult humans 19+ 
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Cochrane Library 
 
 Search Terms 
Term 1  Glaucoma* OR 
Ocular hypertension OR intraocular 
pressure OR intra-ocular pressure  
  
Term 2  Trabeculoplast* OR 
Goniotom* OR 
Trabeculotom* OR 
SLT  
  
Term 3  Prostaglandin analogs OR 
Prostaglandin* OR latanoprost OR 
bimatoprost OR travoprost  
  
Term 4  Beta blocker OR B-blocker OR 
Timolol  OR Betaxolol OR 
Levobutonol  
  
Term 5  Carbonic anhydrase inhibitor* OR 
Carbonate dehydratase 
inhibitor*OR dorzolamide OR 
brinzolamide  
  
Term 6  Alpha-agonist* OR brimonidine 
OR Alphagan  
   
Combined (Term 1 OR Term 2) 
AND (Term 3 OR 4 OR 5 OR 6) 
13 articles included from this 
database using the above search 
strategy. The following limits were 
applied: 
-published 1997- 
Other limits were not applied 
because the options were not 
provided. 
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Grey Literature Sources Search Strategy 
BIOSIS Previews (67) 
 
 
#1.“TOPIC: (glaucoma* or ocular hypertension or 
intraocular pressure or intra-ocular 
pressure) AND TOPIC: (trabeculoplast* or goniotom* 
or trabeculotom* or slt or selective laser 
trabeculoplast) 
Indexes=BIOSIS Previews Timespan=1997-2016” 
(516 articles) 
 
#2. “TOPIC: (Prostaglandin analogs or Prostaglandin* 
or latanoprost or bimatoprost or 
travoprost) OR TOPIC: (Beta blocker* or B-blocker* 
or Timolol or Betaxolol or 
levobutonol) OR TOPIC: (Carbonic anhydrase 
inhibitor* or Carbonate dehydratase inhibitor* or 
dorzolamide or brinzolamide) OR TOPIC: (Alpha-
agonist* or brimonidine or Alphagan) 
Indexes=BIOSIS Previews Timespan=1997-2016” 
(82,787 articles) 
 
#2 AND #1 
Refined by: LANGUAGES: ( ENGLISH ) 
Indexes=BIOSIS Previews Timespan=1997-2016 
 
Web of Science, Core Collection (115) 
 
#1.”TOPIC: ((glaucoma* or ocular hypertension or 
intraocular pressure or intra-ocular 
pressure)) AND TOPIC: ((trabeculoplast* or 
goniotom* or trabeculotom* or slt or selective laser 
trabeculoplast*)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, 
CPCI-SSH, ESCI Timespan=1997-2016” 
 
#2.“TOPIC: (Prostaglandin analogs OR Prostaglandin* 
OR latanoprost OR bimatoprost OR 
travoprost) OR TOPIC: ((Beta blocker OR B-blocker 
OR Timolol OR Betaxolol OR 
Levobutonol)) OR TOPIC: ((Carbonic anhydrase 
inhibitor* OR Carbonate dehydratase inhibitor*OR 
dorzolamide OR brinzolamide)) OR TOPIC: (Alpha-
agonist* OR brimonidine OR Alphagan) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, 
CPCI-SSH, ESCI Timespan=1997-2016” 
 
#2 AND #1 
 
Limits: 1997-present, English Only  
 
Scopus (193) (SLT AND glaucoma OR (Prostaglandin OR Beta-
blockers OR CAIS OR Alpha-agonist) ) 
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Appendix 3: Screening Questions 
 
Level 1 (title screening): 
Does the article look at Selective Laser Trabeculoplasty (SLT) OR SLT AND Beta-Blockers OR 
Prostaglandin analogs OR Carbonic anhydrase Inhibitors, Alpha-agonist and or Open-angle 
glaucoma? 
Yes 
No 
Unclear 
 
Level 2 (abstract screening): 
Are there 20 or more patients/eyes included in the study? 
Yes 
No 
Unclear 
 
Is there a follow-up time of greater than 6 months? 
Yes 
No 
Unclear 
 
 
Is it a research article (exclude systematic reviews and meta-analyses)? (Not an editorial, pilot 
study, or opinion)? 
Yes 
No 
Unclear 
 
 
Level 3 (full article screening): 
Does the study look at SLT compared with medical therapy or does it look at the effect of SLT 
on number of medications? 
Yes 
No 
Unclear 
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Appendix 4: Data Extraction Sheet for Studies Evaluating SLT versus Medications 
 
Author year Slttime Followuptime sltdegree n M_siopr Sd_siopr n m_miopr Sd_miopr 
           
           
 
 
Appendix 5: Data Extraction Sheet for Studies Evaluating SLT as an Adjunctive 
Treatment 
 
Author year sltdegree Followuptime n m_mpre sd_mpre m_mpost sd_mpost 
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Appendix 6: Downs and Black Checklist 
  Description of Criteria Possible 
Answers 
Reporting 1 Is the hypothesis/aim/objective of the study clearly described? Yes/No 
 2 Are the main outcomes to be measured clearly described in 
the Introduction or Methods section? 
Yes/No 
 3 Are the characteristics of the patients included in the study 
clearly described? 
Yes/No 
 4 Are the interventions of interest clearly described? Yes/No 
 5 Are the distributions of principal confounders in each group 
of subjects to be compared clearly described? 
 
 6 Are the main findings of the study clearly described?  Yes/No 
 7 Does the study provide estimates of the random variability in 
the data for the main outcomes?  
Yes/No 
 8 Have all important adverse events that may be a consequence 
of the intervention been reported? 
Yes/No 
 9 Have the characteristics of patients lost to follow-up been 
described? 
Yes/No 
 10 Have actual probability values been reported (e.g. 0.035 
rather than rather than <0.05) for the main outcomes except 
where the probability value is less than 0.001?  
Yes/No 
External 
Validity 
11 Were the subjects asked to participate in the study 
representative of the entire population from which they were 
recruited?  
Yes/No/UTD 
 12 Were those subjects who were prepared to participate 
representative of the entire population from which they were 
recruited?  
Yes/No/UTD 
 13 Were the staff, places, and facilities where the patients were 
treated, representative of the treatment the majority of patients 
receive?  
Yes/No/UTD 
Internal 
Validity-
Bias 
14 Was an attempt made to blind study subjects to the 
intervention they have received? 
Yes/No/UTD 
 15 Was an attempt made to blind those measuring the main 
outcomes of the intervention? 
Yes/No/UTD 
 16 If any of the results of the study were based on “data 
dredging”, was this made clear? 
Yes/No/UTD 
 17 In trials and cohort studies, do the analyses adjust for different 
lengths of follow-up of patients, or in case control studies, is 
the time period between the intervention and outcome the 
same for cases and controls? 
Yes/No/UTD 
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Appendix 6: Downs and Black Quality Checklist (Continued) 
 18 Were the statistical tests used to assess the main outcomes 
appropriate? 
Yes/No/UTD 
 19 Was compliance with the intervention/s reliable? Yes/No/UTD 
 20 Were the main outcome measures used accurate (valid and 
reliable)? 
Yes/No/UTD 
Internal 
Validity-
Confounding 
(selection 
bias) 
21 Were the patients in different intervention groups (trials 
and cohort studies) or were the cases and controls (case-
control studies) recruited from the same population? 
Yes/No/UTD 
 22 Were study subjects in different intervention groups (trials 
and cohort studies) or were the cases and controls (case-
control studies) recruited over the same period of time? 
Yes/No/UTD 
 23 Were study subjects randomised to intervention groups? Yes/No/UTD 
 24 Was the randomised intervention assignment concealed 
from both patients and health care staff until recruitment 
was complete and irrevocable? 
Yes/No/UTD 
 25 Was there adequate adjustment for confounding in the 
analyses from which the main findings were drawn? 
Yes/No/UTD 
 26 Were losses of patients to follow-up taken into account? Yes/No/UTD 
 27 Did the study have sufficient power to detect a clinically 
important effect where the probability value for a 
difference being due to chance 
1-5 
UTD: Unable to Determine 
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